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ABSTRACT
Extracellular Ubiquitin: Role in Cardiac Myocyte Apoptosis and Myocardial Remodeling
by
Christopher Ray Daniels

Activation of sympathetic nervous system is a key component of myocardial remodeling that
generally occurs following ischemia/reperfusion (I/R) injury and myocardial infarction. It
induces cardiac myocyte apoptosis and myocardial fibrosis, leading to myocardial dysfunction.
Intracellular ubiquitin (UB) regulates protein turnover by the UB-proteosome pathway. The
biological functions of extracellular UB in the heart remain largely unexplored. Previously, our
lab has shown that β-adrenergic receptor (β-AR) stimulation increases extracellular UB levels,
and extracellular UB inhibits β-AR-stimulated apoptosis in adult rat ventricular myocytes
(ARVMs). This study explores the role of extracellular UB in myocyte apoptosis, fibroblast
phenotype and function, and myocardial remodeling following β-AR stimulation and I/R injury.
First, left ventricular (LV) structural and functional remodeling was studied 7 days after chronic
β-AR-stimulation in the presence or absence of UB infusion. Echocardiographic analyses
showed UB infusion decreases β-AR-stimulated increases in percent fractional shortening and
ejection fraction. It decreased cardiac myocyte apoptosis and myocardial fibrosis. UB activated
Akt, and inhibition of Akt inhibited β-AR-stimulated increases in matrix metalloproteinase-2
expression. Second, using cardiac fibroblasts, we provide evidence that extracellular UB
interacts with the cell surface and co-immunoprecipitates with CXCR4. UB treatment increased
expression of α-smooth muscle actin (myofibroblast marker), and induced rearrangement of actin
into stress fibers. It inhibited lamellopodia and filopodia formation, and cell migration into the
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wound. Third, using isolated mouse heart and I/R injury as a model, we provide evidence that
UB treatment decreases I/R-mediated increases in infarct size. UB treatment improved functional
recovery of the heart as measured by increased % LV developed pressure. Activation of
proapoptotic proteins, p-STAT-1 and caspase-9, was significantly lower in UB I/R hearts versus
I/R alone. In ARVMs, UB treatment decreased simulated I/R-induced apoptosis. It activated Akt
(anti-apoptotic kinase) and inhibited activation of GSK-3β (pro-apoptotic kinase). It decreased
I/R-induced oxidative stress and protected anoxia-induced mitochondrial polarization. In
fibroblast and ARVMs, CXCR4 antagonism negated the effects of UB, while mutated UBs
(unable to interact with CXCR4) had no effect. Thus, extracellular UB, most likely acting via
CXCR4, modulates myocardial remodeling with effects on heart function, fibroblast phenotype
and function and myocyte apoptosis.
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CHAPTER 1
INTRODUCTION
Cardiovascular disease is the leading cause of death in men and women in the United
States and is responsible for over 29% of all deaths world-wide. Cardiovascular disease is the
number 1 cause of deaths among people over the age of 65 years and the number 2 cause of
deaths in ages 45-64 years. The disease kills more women every year than cancer and stroke.
Over one million people in the United States sustain a myocardial infarction (MI), or
heart attack, every year. An MI occurs when the supply of blood, oxygen, and nutrients to an
area of the heart muscle is blocked. This results in a decrease in function of the heart and causes
sudden death in about half of all victims. For those who survive, the affected heart muscle will
be replaced by scar tissue. However, 19% of women and 26% of men die within 1 year post-MI.
The estimated annual incidence of MI is 515,000 new attacks and 205,000 recurrent attacks, and
the average age at first MI is 64.9 years in men and 72.3 years for women. (Statistic provided by
the American Heart Association and the National Heart Lung and Blood Institute.)

Cardiac Remodeling
Myocardial remodeling refers to the changes in the structure and function of the heart that
commonly occur as a result of heart disease. Adverse myocardial remodeling associates with
poor patient outcomes in the context of ischemic heart disease and/or MI, myocardial
hypertrophy, and other cardiomyopathic disease states. Cardiac remodeling generally associates
with a number of cellular changes including loss of myocytes due to apoptosis (Sharov and
others 1996; Olivetti and others 1997), fibroblast proliferation, and fibrosis (Weber and others
1990; Villarreal and others 1993). These changes clinically manifest as changes in size, shape,
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and function of the heart after myocardial injury (Kehat and Molkentin 2010). The remodeling
process acts as a compensatory mechanism in early stage but becomes deleterious. Cardiac
myocyte apoptosis plays a role in MI (Cohn and others 2000). Apoptosis, programmed cell
death, is a highly organized process. After MI or ischemic event, left ventricular (LV)
dysfunction occurs, in part, as a result of ongoing cardiac myocyte apoptosis (Sharov and others
1996). Cardiac myocyte apoptosis occurs at an increased rate after injury due to ischemia,
reperfusion, and MI (Olivetti and others 1997).
Fibrosis is the excess production and accumulation of extra cellular matrix (ECM)
structural proteins and results in enhanced stiffness of the myocardium and impedes ventricular
contraction and relaxation, leading to distorted architecture and function of the heart (Fan and
others 2012). Cardiac fibroblast play a critical role in the remodeling process of the heart that
occurs in response to MI, hypertension, and heart failure (Souders and others 2009). Activated
fibroblasts are critical in both the reparative and fibrotic processes. In normal tissues resident
fibroblasts are quiescent, producing limited amounts of extracellular matrix proteins and
exhibiting few actin-associated cell-matrix and cell-cell contacts (Tomasek and others
2002).Tissue injury induces alterations in the microenvironment, resulting in differentiation of
fibroblasts into myofibroblasts (Hinz 2007). The matrix metalloproteinases (MMPs) and the
endogenous tissue inhibitor of metalloproteinase inhibitors (TIMPS) play a major role in
remodeling of the ECM. Plasma levels of MMP2 and MMP9 are elevated in MI patients, but
only the MMP9 levels exhibit a biphasic profile that peaked within the first 12 hours and then
fall to a plateau (Webb and others 2006). For example, mice with global deletion of MMP-9
develop normally in the absence of pathophysiological stress, but they show a reduction in the
degree of ventricular dilation and adverse matrix remodeling after myocardial infarction
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(Ducharme and others 2000). Similarly, MMP-2–null mice exhibited a reduction in the rupture
rate after myocardial infarction (Matsumura and others 2005). However, pressure overload
induced by aortic constriction in MMP-2–null mice have shown blunting of the hypertrophic
response (Matsumura and others 2005). Therefore, gene deletion of either MMP-9 or MMP-2 is
associated with significant effects on myocardial matrix remodeling, fibrosis, and whole organ
geometry (Kehat and Molkentin 2010). These findings support a mechanistic role for both MMP2 and -9 in adverse myocardial remodeling processes.

Ischemia/Reperfusion and Myocardial Infarction
Myocardial ischemia is the reduction of blood flow and nutrients, and reperfusion is the
return of blood flow to the myocardium. If the period of acute myocardial ischemia is prolonged,
more than 20min, a “wave front” of cardiomyocyte death occurs in endocardium and extends
over time to the epicardium (Reimer and others 1977). Many biochemical and metabolic changes
occur within the myocardium during ischemia. The absence of oxygen prevents oxidative
phosphorylation, leading to mitochondrial membrane depolarization, ATP depletion, and
inhibition of myocardial contractile function (Hausenloy and Yellon 2013).
Reperfusion is a prerequisite for the survival of ischemic myocardium. Reperfusion or
restoration of blood flow to the ischemic heart limits infarct size and reduces mortality.
However, reperfusion can also result in additional cardiac damage, referred as reperfusion injury.
Reperfusion injury is a complex process that includes rapid restoration of physiological pH,
oxidative stress, intracellular Ca++ overload, and mitochondrial damage. During reperfusion,
physiological pH is rapidly restored by the removal of lactate and the activation of the Na+-H+
exchanger as well as the Na+-HCO- symporter (Hausenloy and Yellon 2013). The change in pH
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leads to cardiomyocyte apoptosis by allowing mPTP opening and cardiomyocyte
hypercontracture in the first few minutes of reperfusion (Lemasters and others 1996). Shortly
after reperfusion the electron transport chain is reactivated causing an increase in reactive
oxygen species (ROS). ROS is also produced by xanthine oxidase in endothelial cells and
NADPH oxidase released during an influx of neutrophils (Brechard and Tschirhart 2008; Frey
and others 2009). This leads to oxidative damage of DNA, proteins, and the sarcoplasmic
reticulum causing intracellular Ca++ overload (Dejeans and others 2010). Intracellular and
mitochondrial Ca++ overload starts during ischemia. However, reperfusion accelerates the process
due to disruption of the plasma membrane, oxidative stress-induced damage to the sarcoplasmic
reticulum, and mitochondrial re-energization (Hausenloy and Yellon 2013; Rodrigo and others
2013). Mitochondrial re-energization is the recovery of the mitochondrial membrane potential
that causes the entry of Ca++ into the mitochondria and induces the opening of the mPTP (Fig
1.1). A severe microvascular dysfunction may limit adequate perfusion after reperfusion. This
‘no flow’ phenomenon occurs in about 30% of patients and associates with an increased
incidence of acute MI, myocardial rupture, and death (Moens and others 2005).

16

Figure 1.1. Cascade of Events Due to Ischemia/Reperfusion Injury. ROS, reactive oxygen
species; mPTP, mitochondrial membrane permeability transition pore.
β-Adrenergic Receptor Stimulation and Heart Disease
Increased sympathetic nerve activity to the myocardium is a central feature in patients
with heart failure (Hasking and others 1986), and chronic exposure to catecholamines is known
to be toxic to cardiac myocytes (Rona 1985). Chronic β-adrenergic receptor (β-AR) stimulation
potentiates myocardial ischemia/reperfusion (I/R) injury (Hu and others 2006). Initial release of
catecholamines by the sympathetic nervous system exerts important tonic effects on the biology
of cardiac myocytes leading to increased contractility. However, chronic increase in sympathetic
activity is known to have adverse effects in the heart. The efficacy of β-AR antagonist in
improving the clinical outcome as well as benefit in long-term morbidity and mortality of
17

patients with chronic heart failure (Bristow 2000) has confirmed the importance of sympathetic
nerve activity in the pathological remodeling, a process that leads to progressive left ventricular
dilation and contractile dysfunction. Norepinephrine, a primary neurotransmitter of sympathetic
nervous system, signals via its interaction with α- and β-AR, a family of G protein-coupled
receptors. Specific stimulation of β-AR using norepinephrine or isoproterenol (β-AR agonist)
induces apoptosis in cardiac myocytes in vitro and in vivo (Singh and others 2001; Goldspink
and others 2004; Krishnamurthy and others 2007). Increased myocyte apoptosis may influence
the development of heart failure.

β-AR-Stimulation and Cardiac Myocyte Apoptosis
Stimulation of -AR induces apoptosis in cardiac myocytes in vitro and in vivo
(Shizukuda and others 1998; Iwai-Kanai and others 1999; Zaugg and others 2000; Singh and
others 2001). Three subtypes of β-AR have been identified (β1, β2, β3) (Hadcock and Malbon
1993), and all 3 types are expressed on cardiac myocytes (Devic and others 2001). β1-AR is the
most abundant receptor type in cardiac myocytes. However, the ratio of β1 to β2-AR varies
among species and under various pathophysiological states (Bristow 2000). Both β1- and β2-AR
couple to the stimulatory G protein (Gαs) (Amin and others 2011). This coupling leads to
activation adenylyl cyclase and production of cAMP a common second messenger. β2-AR can
also couple to a Gi, a different heterodimeric G-protein whose Gα subunit inhibits adenylyl
cyclase and synthesis of cAMP. However, this coupling may require phosphorylation of β2-AR
by cAMP-dependent protein kinase A (Daaka and others 1997). Stimulation of β1-AR-Gs and
activation of PKA induces myocyte apoptosis (Communal and others 1999; Shizukuda and
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Buttrick 2002), while stimulation of β2-AR-Gi and activation of phosphatidylinositol 3-kinase
(PI3-kinase) and Akt inhibit apoptosis (Xiao 2001).
Mitogen activated protein kinases (MAPKs), a large family of serine-threonine kinases,
have important functions as mediators of intracellular signal transduction (Figure 1.2). Three
subgroups of MAPKs have been identified: c-jun N-terminal kinases (JNKs), p38 kinase, and
ERK1/2 (Cargnello and Roux 2011). β-AR stimulation has been shown to activate these 3
subgroups of MAPKs (Communal and others 2000). Activation of JNKs plays a proapoptotic
role (Remondino and others 2003). Activation of p38 kinase plays a protective role in β-ARstimulated myocyte apoptosis, and inhibition of ERK1/2 using PD98059 had no effect on β-ARstimulated apoptosis (Communal and others 2000). Superoxide dismutase/catalase-mimetics or
catalase overexpression inhibited JNK activation and β-AR-stimulated apoptosis (Remondino
and others 2003). Inhibition of mitochondrial permeability transition pore opening or caspase
activation decreases β-AR-stimulated apoptosis (Remondino and others 2003). These studies
suggest that β-AR-stimulated apoptosis in adult rat ventricular myocytes involves reactive
oxygen species/JNK-dependent activation of the mitochondrial death pathway. β-AR stimulation
also activates glycogen synthase kinase-3β (GSK-3β), and activation of GSK-3β plays a
proapoptotic role in β-AR-stimulated apoptosis via the involvement of mitochondrial death
pathway (Novikoff and others 1975). Adenoviral-mediated overexpression of constitutively
active GSK-3β increased JNK phosphorylation, suggesting that GSK-3β may also act upstream
in the activation of JNKs (Singh and others 2010).
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Figure 1.2 Summary Diagram Illustrating Signaling Pathways Involved in β-AR-Stimulated
Cardiac Myocyte Apoptosis. AR: adrenergic receptors; JNKs: c-Jun-N-terminal kinase; GSK-3β:
glycogen synthase kinase-3β; ROS: reactive oxygen species; PKA: protein kinase A; AC:
adenylyl cyclase; Gs: stimulatory G protein; Gi: inhibitory G protein; ATP: adenosine
triphosphate; cAMP: cyclic adenosine monophosphate; CaMKIIδ: calcium calmodulin kinase
IIδ; PI-3K: phosphatidylinositol 3-kinase. (Source Amin 2011)
β-AR-Stimulation and Myocardial Fibrosis
In heart failure the sympathetic system is overactivated and leads to formation of cardiac
fibrosis, which contributes to the aggravation of cardiac function (Bos and others 2005). Cardiac
fibrosis results from proliferation of interstitial fibroblasts and concomitant increased
biosynthesis of ECM components. Isoproterenol (β-AR agonist) has been shown to produce
increased fibrosis and hypertrophy (Krishnamurthy and others 2007). Greater cardiac fibrosis in
20

Brown Norway rats treated with isoproterenol correlates with the early and higher expression of
proinflammatory factors (Copaja and others 2008). Isoproterenol-induced myocardial fibrosis is
initiated by the appearance of interstitial edema and fibrillar collagen disruption and is followed
soon thereafter by the formation of thinner collagen fibers that extend across muscle fibers and
into which thicker collagen fibers become entwined in a crisscrossing pattern. Once formed, this
mesh of collagen fibers encircles cardiac muscle (Pick and others 1989). It is also interesting to
note that stimulation of β-AR increases expression and activity of MMP-2 and MMP-9 in cardiac
myocytes and in the heart (Menon and others 2005; Krishnamurthy and others 2007). Thus,
deposition of fibrosis may represent a complex function of both collagen synthesis and
degradation.

Ubiquitin
Ubiquitin is a small heat-stable protein (~ 8.5 kDa) found in all eukaryotic cells
(Ciechanover and others 1980; Ozkaynak and others 1984). Its amino acid sequence is highly
conserved between animal species with only 2-3 amino acid residues differing between yeast and
human (Wilkinson and others 1986). Ubiquitin is a well-known posttranslational protein
modifier and covalent ligation of ubiquitin to intracellular proteins is known as ubiquitination or
ubiquitylation. This process is catalyzed by ubiquitin protein ligase systems (Bairoch 2000). The
ubiquitin protein ligase system consist of 3 enzymes and leads to the degradation of proteins
through the ubiquitin proteosome pathway (Hershko and Ciechanover 1998). In the ubiquitinproteosome pathway ubiquitination is the signal for degradation of the target protein by the 26S
proteosome (Hershko and Ciechanover 1998; Schwartz and Ciechanover 2009). Ubiquitination
leads to a polyubiquitin tag and is required for protein degradation by the proteosome (Hicke
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2001). Following phosphorylation, ubiquitination is the second most common posttranslation
protein modification (Weissman 2001; Haataja and others 2002).
Ubiquitin is a normal plasma protein. Normal ubiquitin concentrations in human plasma
and serum lies in the low nanomolar range (<10nM ; <100ng/mL) (Okada and others 1993;
Okada and others 1995). Ubiquitin is also detectable in cerebral spinal fluid (CSF),
bronchoaveolar lavage fluid (BALF), seminal plasma, and urine. Ubiquitin concentrations are 3
to 5 folds lower in CSF than what is found in circulation. However, normal urine concentrations
are slightly lower than serum concentrations (Majetschak and others 2003; Pisitkun and others
2004). Higher ubiquitin concentrations in systemic circulation have been reported in multiple
diseases such as; allergic, autoimmune, infections, and kidney failure (Asseman and others 1994;
Okada and others 1995; Akarsu and others 2001b; Majetschak and others 2003). Extracellular
ubiquitin is proposed to have pleotropic effects on hematopoiesis, leukocytes, and platelets and
possess antimicrobial activity (Kagan and others 1977; Kagan and others 1979; Pancre and
others 1991; Kieffer and others 2003).
The G protein–coupled receptor CXC chemokine receptor (CXCR)4 is abundantly
expressed in immune cells and tissues, including cardiac fibroblast (Hu and others 2007).
CXCR4 plays an important role in a variety of biological processes and is suggested to be
involved in the pathophysiology of various disease processes such as cancer, HIV, ischemic
myocardial injury, and angiogenesis (Tripathi and others 2013). Stromal derived factor-1α (SDF1α) is the cognate ligand for CXCR4 that is implicated in homing of hematopoietic stem cells
during wound repair (Chu and others 2010). SDF-1α is shown to have cardioprotective effects
against ischemia/reperfusion injury by promoting antiapoptotic program (Hu and others 2007).
Interestingly, CXCR4 is identified as a receptor for UB in THP1 leukemia cell line (Saini and
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others 2010). Using C-terminal truncated ubiquitin and ubiquitin mutants, Saini et al. provide
evidence that the ubiquitin-CXCR4 interaction follows a 2-site binding mechanism in which the
hydrophobic surfaces surrounding Phe-4 and Val-70 are important for receptor binding, whereas
the flexible C terminus facilitates receptor activation (Saini and others 2011).

Extracellular UB and β-AR-Stimulated Myocyte Apoptosis
As discussed above, β-AR stimulation induces apoptosis in adult cardiac myocytes.
However, β-AR stimulation induces apoptosis only in a fraction (∼15–20%) of myocytes,
although all the cells are exposed to the same stimulus. Previously, a search to identify survival
factor(s) secreted or released by myocytes that protect 80–85% of cells from apoptosis (in our
lab) using 2-dimensional gel electrophoresis followed by MALDI TOF and MS/MS, led to
identification of UB in the conditioned media of myocytes treated with β-AR agonist
(isoproterenol) (Singh and others 2010). Inhibition of β1-AR and β2-AR subtypes inhibited βAR-stimulated increases in extracellular levels of UB, whereas activation of adenylyl cyclase
using forskolin mimicked the effects of β-AR stimulation. Pretreatment with UB inhibited β-ARstimulated increases in apoptosis. Inhibition of phosphoinositide 3-kinase using wortmannin and
LY-294002 prevented antiapoptotic effects of extracellular UB. UB pretreatment inhibited βAR-stimulated activation of GSK-3β and JNK and increases in the levels of cytosolic
cytochrome c. The use of methylated UB suggested that the antiapoptotic effects of extracellular
UB are mediated via monoubiquitination. Together, these studies suggested that β-AR
stimulation increases levels of UB in the conditioned media. Extracellular UB plays a protective
role in β-AR-stimulated apoptosis, possibly via the inactivation of GSK-3β/JNK and
mitochondrial pathways (Singh and others 2010).
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Specific Aims
The overall goal of the present study was to further understand the role extracellular
ubiquitin plays in cardiac myocyte apoptosis, the signaling mechanisms involved, and the
implications in the processes of cardiac remodeling. We hypothesized that extracellular ubiquitin
modulates cardiac myocyte apoptosis and fibroblast phenotype and function, thereby modulating
chronic β-AR receptor-stimulated and I/R-induced myocardial remodeling. The specific aims of
the study were as follows: 1) investigate the in vivo role of exogenous ubiquitin in β-ARstimulated myocardial remodeling with effects on LV function, fibrosis, and myocyte apoptosis;
2) study the role of extracellular ubiquitin in modulation of cardiac fibroblast phenotype and
function; and 3) determine the effect of extracellular ubiquitin on the process of myocardial I/R
injury at the cellular and tissue levels.
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Abstract
β-adrenergic receptor (β-AR) stimulation increases extracellular ubiquitin (UB) levels, and
extracellular UB inhibits β-AR-stimulated apoptosis in adult cardiac myocytes. This study
investigates the role of exogenous UB in chronic β-AR-stimulated myocardial remodeling. Lisoproterenol (ISO; 400µg/kg/h) was infused in mice in the presence or absence of UB (1g/g/h).
Left ventricular (LV) structural and functional remodeling was studied 7 days after infusion. UB
infusion enhanced serum UB levels. In most parts, UB alone had no effect on morphometric or
functional parameters. Heart weight-to-body weight ratios were increased to a similar extent in
ISO and UB+ISO groups. Echocardiographic analyses showed increased percent fractional
shortening, ejection fraction and LV circumferential stress and fiber shortening velocity in ISO
group. These parameters were significantly lower in UB+ISO vs ISO. Isovolumic contraction
and relaxation times, and ejection time were significantly lower in ISO vs UB+ISO. The increase
in the number of TUNEL-positive myocytes and fibrosis was significantly higher in ISO vs
UB+ISO. Activation of Akt was higher, while activation of GSK-3β and JNKs was lower in
UB+ISO vs ISO. Expression of MMP-2, MMP-9 and TIMP-2 was higher in UB+ISO vs ISO. In
isolated cardiac fibroblasts, UB enhanced expression of MMP-2 and TIMP-2 in the presence of
ISO. Neutralizing UB antibodies negated the effects of UB on MMP2 expression, while
recombinant UB enhanced MMP-2 expression. UB activated Akt, and inhibition of Akt inhibited
UB+ISO-mediated increases in MMP-2 expression. Thus, exogenous UB plays an important role
in β-AR-stimulated myocardial remodeling with effects on LV function, fibrosis and myocyte
apoptosis.
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Introduction
Ubiquitin (UB), a highly conserved protein of ~8.5 kDa, is found in all eukaryotic cells.
The most important intracellular function of UB is to regulate protein turnover by the ubiquitinproteasome pathway (15). The ubiquitin-proteasome pathway may regulate receptor
internalization, hypertrophic response, apoptosis, and tolerance to ischemia and reperfusion in
cardiac myocytes (56). UB is a normal constituent of plasma. Elevated levels of UB are
described in the serum or plasma of patients with parasitic and allergic diseases (4), alcoholic
liver disease (48), type 2 diabetes (1), β2-Microglobulin amyloidosis (34) and chronic
hemodialysis patients (2). Patients with traumatic brain injury are shown to have increased UB
levels in the cerebrospinal fluid (28). Extracellular UB is proposed to have pleiotropic functions
including regulation of immune response, anti-inflammatory and neuroprotective activities (27;
29; 36), as well as growth regulation and apoptosis control in hematopoetic cells (9). The
biological functions of extracellular UB in the heart remain largely unexplored. Specifically, the
role of exogenous UB in myocardial remodeling has not yet been investigated.
Sympathetic nerve activity increases in the heart during cardiac failure. Prolonged
stimulation of the β-adrenergic neurohormonal axis contributes to the progression of heart failure
and mortality in animal models and human patients (13; 43). Stimulation of -adrenergic
receptor (β-AR) increases expression and activity of matrix metalloproteinase (MMP-2 and
MMP-9) in cardiac myocytes in vitro and in vivo (23; 31). It induces apoptosis in cardiac
myocytes in vitro and in vivo (19; 42; 43; 55). b-AR-stimulated apoptosis in adult rat ventricular
myocytes (ARVMs) is demonstrated to occur via the GSK-3β-/JNK-dependent mitochondrial
death pathway (30; 39). Recently, we provided evidence that stimulation of β-AR increases
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extracellular levels of UB in ARVMs, and extracellular UB plays a protective role in β-ARstimulated apoptosis via the inactivation of GSK-3β and JNKs pathways (44).
Here, we investigated the in vivo role of exogenous UB in cardiac myocyte apoptosis and
myocardial remodeling following chronic β-AR stimulation in mice. We report that exogenous
UB plays an important role in β-AR-stimulated myocardial remodeling with effects on left
ventricular function, fibrosis and myocyte apoptosis. It may inhibit myocyte apoptosis via the
activation of Akt and inactivation of GSK-3β and JNKs, while inhibits fibrosis by modulating
expression and activity of MMPs and TIMPs.

Methods and Material
Experimental Animals
The investigation conforms with the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
The animal protocol was approved by the University Committee on Animal Care. Animals were
anesthetized using a mixture of isoflurane (2.5%) and oxygen (0.5 l/min) and the heart was
excised following a bilateral cut in the diaphragm. Mice were euthanized by exsanguination. The
studies were performed using male ICR mice (25-30 g; purchased from Harlan Lab.).

Mice Treatment
Mice were randomly assigned to 4 groups (sham, ISO, UB+ISO and UB). The mice in
UB+ISO and UB groups received intraperitoneal injection of UB (1 g/g; U6253; Sigma) 1h
prior to pump implantation. The mice were infused with ISO (isoproterenol; 400 g/kg/h; ISO
group), UB+ISO (1 g/g/h+400 g/kg/h; UB+ISO group) and UB (1µg/g/h; UB group) at the
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rate of 1.0 l/h for 7 days using mini-osmotic pumps (Alzet Corp.). L-isoproterenol and UB were
dissolved in acidified isotonic saline (0.001 N HCl). Sham animals were infused with acidified
isotonic saline solution. The dose of ubiquitin and ISO were selected based on previously
published reports (14; 23; 42).

Echocardiography
Transthoracic two-dimensional M-mode echocardiogram and pulsed wave Doppler
spectral tracings were obtained using a Toshiba Aplio 80 Imaging System (Tochigi, Japan)
equipped with a 12 MHz linear transducer (12; 23). Echocardiographic procedures were
performed prior to and 7 days after implantation of pumps. The animals were anesthetized during
procedure using a mixture of isoflurane (1.5%) and oxygen (0.5 l/min), and their body
temperature maintained at ~37°C using a heating pad. M-mode tracings were used to measure
LV end-systolic diameter (LVESD) and end-diastolic diameter (LVEDD). Percent fractional
shortening (%FS) and ejection fraction (EF%) were calculated as described (12; 23). Doppler
tracings of mitral and aortic flow were used to measure isovolumic relaxation time (IVRT),
isovolumic contraction time (IVCT) and ejection time (ET). LV circumferential stress and fiber
shortening velocity (Vcf) was calculated as = LVEDD – LVESD / LVEDD x LVET, where
LVEDD and LVESD are LV diastolic and systolic diameters, respectively, and LVET is LV
ejection time (38). All echocardiographic assessments were performed by the same investigator
blinded to the treatments. A second person also performed measurements on a separate occasion
using the same recordings with no significant differences in interobserver variability.
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Morphometric Analyses
Animals were euthanized and the hearts were arrested in diastole using KCl (30 mM)
followed by perfusion fixation with 10% buffered formalin. Cross sections (4 µm thick) were
stained with Masson’s trichrome for the measurement of fibrosis using Bioquant image analysis
software (Nashville, TN).

Measurement of Serum UB Levels
Serum UB levels, 7 days after ISO-infusion, were measured using ELISA kit (Novatein
Biosciences).

Myocyte Cross-Sectional Area
Heart sections (4 µm thick) were deparaffinized and stained with TRITC-labeled wheat
germ agglutinin (WGA). The sections were visualized using fluorescent microscopy (20X;
Nikon) and images were recorded using Retiga 1300 color-cooled camera. Suitable area of the
sections was defined as the one with nearly circular capillary profiles.

TUNEL Staining
To measure apoptosis, terminal deoxynucleotidyl transferase-mediated dUTP nick endlabeling (TUNEL) staining followed by Hoechst 33258 staining was carried out on 4 µm-thick
paraffin-embedded sections as per manufacturer’s instructions (Cell death detection assay kit,
Roche). To identify apoptosis associated with cardiac myocytes, the sections were
immunostained using -sarcomeric actin antibodies (1:50; 5C5 clone, Sigma, St Louis, MO).
Hoechst 33258 (10 µM; Sigma, St Louis, MO) staining was used to count the total number of
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nuclei. TUNEL-positive nuclei that were clearly seen within cardiac myocytes were counted.
The number of apoptotic cardiac myocyte nuclei was counted and index of apoptosis was
calculated as the percentage of apoptotic myocyte nuclei/total number of nuclei.

Fibroblast Isolation and Treatment
Adult rat cardiac fibroblasts were isolated as described (53). The cells were grown to
confluence and serum-starved for 48 h before use. First and second passage cells were used for
all the experiments. The cells were pretreated with UB (10 µg/ml; Sigma) for 30 min followed
by treatment with ISO for indicated time points. To neutralize effects of UB, cells were
pretreated with anti-UB antibodies (5 µg/ ml; U5379; Sigma) for 30 min. To verify effects of
UB, cells were pretreated with recombinant UB (rUB; 10 or 100 µg/ml; Boston Biochem) for 30
min followed by treatment with ISO for 48 h. To inhibit Akt, cells were pretreated with MK2206 (1 μM; Chemie Tek) for 30 min, then with UB (10 µg/ml) for 30 min followed by
treatment with ISO.

Western Analysis
LV tissue lysates were prepared in RIPA buffer [10 mM Tris-HCl (pH 7.2), 158 mM
NaCl, 1 mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 1 mM sodium
orthovanadate, 0.2 mM phenylmethylsulfonyl fluoride] using a tissue homogenizer. Cell lysates
were prepared using lysis buffer [10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1 mM
EDTA, 0.2 mM sodium orthovanadate, 0.5% Nonidet P-40, 1% Triton X-100, and 1 mM
phenylmethylsulfonyl fluoride]. Equal amounts of total proteins (70 μg from tissue lysates or 20
µg from cell lysates) were resolved on 10% SDS-polyacrylamide gels. The proteins were
transferred onto PVDF membrane. The blots were then probed with primary antibodies directed
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against p-Akt (1:1000; Cell Signaling Tech.), p-GSK-3β (1:1000; Cell Signaling Tech.), p-JNKs
(1:1000; Millipore), p-ERK1/2 (1:2000; Cell Signaling Tech.), MMP-2 (1:5000; Millipore),
MMP-9 (1:5000; Millipore), or TIMP-2 (1:1000; Santa Cruz) and appropriate secondary
antibodies. Membranes were then stripped and probed with Akt, GSK-3β, JNKs, ERK1/2, actin
(Chemicon) or GAPDH (Santa Cruz) antibodies to normalize protein loading. Band intensities
were quantified using Kodak photo documentation system (Eastman Kodak Co.).

In-gel Zymography
Gelatin in-gel zymography in the concentrated conditioned media of fibroblasts (2 µg) or
LV (50 µg) lysates was performed as described (53). Clear and digested regions representing
MMP-2 activity were quantified using a Kodak documentation system.

Statistical Analysis
Data are expressed as the mean  SEM. Data was analyzed using Student’s t test or a
one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test.
Probability (P) values of <0.05 were considered to be significant.

Results
Morphometric Studies
None of the animals died during the course of the experiment. No significant change in
body weight (BW) in any group was observed during the experiment. ISO-infusion increased
heart weight (HW) as well as the HW/body weight (HW/BW) ratios in ISO and UB+ISO groups
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as compared to sham (p<0.05; Table 2.1) with no significant difference between the two ISO
groups. UB alone had no effect on HW or HW/BW ratio.
Table 2.1. Morphometric Measurements
SHAM

ISO

UB+ISO

UB

(n=6)

(n=6)

(n=6)

(n=6)

P value

BW (g)

30.27±1.00

31.95±0.86

31.60±0.64

31.00±0.76

NS

HW (mg)

129.7±6.74

167.4±8.98*

178.6±7.46*

144.5±10.8

*<0.01

HW/BW (mg/g)

4.29±0.21

5.22±0.17*

5.65±0.21*

4.65±0.29

*<0.01

Parameters

HW, heart weight; BW, body weight. Values are mean±SEM; *comparison versus SHAM
group; NS, not significant.

Serum UB Levels
Measurement of serum UB levels using ELISA demonstrated presence of 16.2±1.3ng/ml
UB in sham animals. ISO had no effect on serum UB levels. Serum UB levels were increased in
UB-infused groups when compared to sham or ISO groups (P<0.05; Fig 2.1). However, the
increase in serum UB levels was higher in UB alone when compared to UB+ISO group.

Figure 2.1. Serum UB Levels. UB infusion increases serum UB levels. *P<0.05 versus sham;
#
P<0.05 versus ISO; $P<0.05 vs UB+ISO; n=5-6.
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Echocardiographic Measurements
M-mode echocardiography showed no significant difference in LVESD, LVEDD, %FS
and EF% between sham and UB groups. ISO-infusion decreased LVESD in ISO, not in
UB+ISO, group. LVEDD remained unchanged between the two groups. %FS, EF% and Vcf
were increased in ISO, not in UB+ISO, group when compared to sham. In fact, %FS, %EF and
mean Vcf were significantly lower in UB+ISO when compared to ISO group (Table 2.2).
Table 2.2. M-mode Echocardiographic Measurements
SHAM
ISO
UB+ISO
Parameters

UB

(n=6)

(n=6)

(n=6)

(n=5)

P value

LVESD (mm)

2.73±0.04

2.36±0.06*

2.78±0.06#

2.74±0.16

*<0.05; #<0.05

LVEDD (mm)

3.90±0.08

3.89±0.02

4.11±0.06

3.97±0.16

NS

%FS

30.01±0.99

39.26±1.55*

32.50±1.03#

31.31±1.88

*<0.01;#<0.05

EF%

57.73±1.39

70.07±2.02*

61.14±1.45#

59.51±2.84

*<0.01; #<0.05

Mean Vcf (circ/sec)

5.99±0.23

10.10±0.62*

6.97±0.28#

6.09±0.39

*<0.001;#<0.001

Values are mean±SEM; LVESD, LV end-systolic diameter; LVEDD, LV end-diastolic diameter;
%FS, percent fractional shortening; EF%, percent ejection fraction; Vcf, mean velocity of
circumferential shortening; *comparison versus SHAM group; #comparison versus ISO group;
NS, not significant.

Doppler tracings revealed no difference in any parameters between sham and UB groups
(Table 2.3). ISO-infusion decreased IVRT, IVCT, and ET in both groups when compared to
sham. However, decrease in these parameters was significantly lower in ISO when compared to
UB+ISO group (p<0.05; Table 2.3). ISO-infusion increased heart rates in both groups with no
significant difference between ISO and UB+ISO groups.
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Table 2.3. Doppler Echocardiographic Measurements
SHAM
ISO
UB+ISO
Parameters
IVRT (ms)
IVCT (ms)
ET (ms)
HR (bpm)

(n=6)
12.41±0.01
11.98±0.01

(n=6)

UB

(n=6)

5.07±0.01*

(n=5)

P value

#

12.98±0.01

*<0.05; #<0.01

#

13.11±0.01

*<0.01; #<0.001

7.26±0.01*

5.19±0.01*

7.67±0.01*

#

50.22±0.01

39.07±0.01*

46.70±0.01*

51.47±0.01

*<0.05;#<0.001

428.37±19.36

572.87±23.7*

506.98±17.98*

388.64±18.31

*<0.05

Values are mean±SEM; IVRT, isovolumetric relaxation time; IVCT, isovolumetric contraction
time; ET, ejection time ; HR, heart rate ; *comparison versus SHAM group; #comparison versus
ISO group; NS, not significant.

Fibrosis, Apoptosis and Hypertrophy
ISO-infusion increased fibrosis in both groups (Fig 2.2A). Quantitative analysis of
trichrome-stained sections showed that the increase in fibrosis was significantly lower in the
UB+ISO group when compared to ISO (percent fibrosis, WT-sham, 0.17  0.05; ISO, 1.78 
0.15*; UB+ISO, 1.09  0.16*#; UB, 0.29 ± 0.13; *P<0.01 vs Sham; #P<0.05 vs ISO; n = 5-6; Fig
2.2B).
ISO-infusion increased the number of TUNEL-positive myocytes in both groups.
However, the percentage of apoptotic myocytes was significantly lower in UB+ISO group when
compared to ISO (percentage of apoptotic myocyte nuclei/total number of nuclei; Sham, 0.07 ±
0.03; ISO, 0.35 ± 0.07*; UB+ISO, 0.15 ± 0.05#; UB, 0.02 ± 0.01; *P<0.01 vs Sham; #P<0.05 vs
ISO; n = 3-5; Fig 2.2C).
ISO-infusion increased myocyte cross-sectional area to a similar extent in both groups
when compared to sham (µm2; Sham, 137.5 ± 8.5; ISO, 297.4 ± 9.2*; UB+ISO, 227.3 ± 28.5*;
UB, 149 ± 4.8; *P<0.01 vs Sham; n = 3-4; Fig 2.2D).

35

Figure 2.2. Myocardial Remodeling 7 Days after ISO-Infusion. A & B) Analysis of fibrosis.
Panel A exhibits Masson’s trichrome-stained sections 7 days after ISO-infusion. Panel B shows
quantitative analysis of fibrosis. *P<0.01 versus sham; #P<0.05 versus ISO; n = 5-6. C)
Quantitative analysis of TUNEL-stained myocytes 7 days after ISO-infusion. *P<0.01 versus
sham; #P<0.05 versus ISO; n = 3-5. D) Quantitative analysis of myocyte cross-sectional area.
*P<0.01 versus sham; n = 3-4.
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Activation of Akt and GSK-3β
Previously, we have provided evidence that inhibition of PI3-kinase inhibits the
protective effects of UB in β-AR-stimulated apoptosis in ARVMs (44). PI3-kianse activates Akt
and activation of Akt plays an anti-apoptotic role (22). Western blot analysis of LV lysates using
phospho-specific anti-Akt antibodies showed a significant increase in Akt phosphorylation
(activity) in both ISO and UB+ISO groups when compared to sham. However, the increase in
Akt activity was significantly higher in UB+ISO group when compared to ISO (p<0.05; Fig
2.3A). UB alone had no effect on Akt activity.
Activation of GSK-3β plays a pro-apoptotic role in β-AR-stimulated apoptosis (30).
Phosphorylation of an N-terminal serine residue (serine-9) inactivates GSK-3β. Akt is one of the
upstream kinases involved in phosphorylation (serine-9) and inactivation of GSK-3β (16).
Western blot analysis of LV lysates using phospho-specific anti-GSK-3β antibodies showed
decreased phosphorylation (activation) of GSK-3β in ISO, not in UB+ISO, group. GSK-3β
phosphorylation was significantly higher in UB+ISO when compared to ISO group (WT-sham,
0.76±0.1; ISO, 0.46±0.04*; UB+ISO, 0.64±0.04#; UB, 0.57±0.1; *P<0.05 vs Sham; #P<0.05 vs
ISO; n = 4-7; Fig 2.3B). UB alone had no effect on GSK-3β phosphorylation.
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Figure 2.3. Activation of Akt and GSK-3β in the Heart. Total LV lysates (70 µg), were analyzed
by western blot using phospho-specific Akt (serine-473), total Akt, phospho-specific GSK-3β
(serine-9) and total GSK-3β antibodies. The lower panels exhibit mean data normalized to total
Akt or GSK-3β. A) Phosphorylation (activation) of Akt. *P<0.05 versus sham; #P<0.05 versus
ISO; n = 6. B) Phosphorylation (inactivation) of GSK-3β. *P<0.05 versus sham; #P<0.01 versus
ISO; n = 4-7.

Activation of JNKs and ERK1/2
β-AR-stimulated activation of c-Jun NH2-terminal kinase (JNK) pathway is demonstrated
to play a pro-apoptotic role in β-AR-stimulated apoptosis (39). Previously, we have provided
evidence that active GSK-3β may act upstream in the activation of JNKs (44). Western blot
analysis of LV lysates using phospho-specific anti-JNKs antibodies showed increased
phosphorylation (activation) of JNKs in ISO, not in UB+ISO, group. Activation of JNKs was
significantly lower in UB+ISO group when compared to ISO (WT-sham, 0.68±0.16; ISO,
4.32±0.35; UB+ISO, 1.88±0.59#; UB, 0.99±0.43; *P<0.05 vs Sham; #P<0.05 vs ISO; n = 4-7;
Fig 2.4A). UB alone had no effect on JNKs phosphorylation. ISO in the presence or absence of
UB had no effect on the activation of ERK1/2 (Fig 2.4B).
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Figure 2.4. Activation of JNKs and ERK1/2 in the Heart. Total LV lysates (70 µg), were
analyzed by western blot using phospho-specific JNKs, total JNKs, phospho-specific ERK1/2
and total ERK1/2. The lower panels exhibit mean data normalized to total JNKs or ERK1/2. A)
Phosphorylation (activation) of JNKs. *P<0.05 versus sham; #P<0.05 versus ISO; n = 6. B)
Phosphorylation (activation) of ERK1/2; n = 5.

Expression and Activation of MMP-2 and MMP-9
MMPs (MMP-2 and MMP-9) play a significant role in myocardial fibrosis and
remodeling (46). Western blot analysis of LV lysates demonstrated increased expression (protein
levels) of MMP-2 in both ISO groups (Fig 2.5A). However, the increase in MMP-2 expression
was significantly higher in UB+ISO group when compared to ISO. In gel zymography showed
increased MMP-2 activity in both ISO groups. However, the increase in MMP-2 activity was
significantly higher in UB+ISO group when compared to ISO (Fig 2.5B). Increased MMP-9
expression was only observed in UB+ISO group (WT-sham, 0.79±0.1; ISO, 0.73±0.1; UB+ISO,
1.16±0.1*#; UB, 0.66±0.2; *P<0.05 vs Sham; #P<0.05 vs ISO; n = 6; Fig 2.6A). In gel
zymography failed to show active MMP-9 bands in the LV lysates from these groups (data not
shown).
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Figure 2.5. Expression and Activation of MMP-2 in the Heart. Total LV lysates (70µg) were
analyzed by western blot (using anti-MMP-2 antibodies) or gelatin in-gel zymography. A)
Expression of MMP-2. GAPDH immunostaining indicates protein loading. *P<0.05 versus
sham; #P<0.05 versus ISO; n = 6. B) MMP-2 activity. *P<0.01 versus sham; #P<0.05 versus ISO;
n = 4.
Expression of TIMP-2 and TIMP-4
Tissue inhibitors of MMPs (TIMPs) play an important role in regulation of MMPs
activity (32; 51). Western blot analysis of LV lysates demonstrated that ISO alone has no effect
on TIMP-2 protein levels. However, UB alone or in the presence of ISO significantly increased
TIMP-2 protein levels (Fig 2.6B). ISO in the presence or absence of UB had no effect on protein
levels of TIMP-4. UB alone increased TIMP-4 protein levels when compared to ISO or UB+ISO
groups (data not shown).
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Figure 2.6. Expression of MMP-9 and TIMP-2 in the Heart. Total LV lysates (70µg) were
analyzed by western blot using anti-MMP-9 or anti-TIMP-2 antibodies. GAPDH
immunostaining indicates protein loading. A) Expression of MMP-9. *P<0.05 versus sham;
#
P<0.05 versus ISO; n = 6. B) Expression of TIMP-2. *P<0.01 versus sham; #P<0.05 versus ISO;
n = 4.

UB Modulates Expression of MMPs and TIMP-2 in Cardiac Fibroblasts
ISO treatment increased MMP-2 expression in adult cardiac fibroblasts as analyzed by
western blots. However, the increase in MMP-2 expression was significantly higher in UB+ISO
group when compared to ISO (Fig 2.7A). In-gel zymography showed a trend towards increased
MMP-2 activity in response to ISO. However, MMP-2 activity was significantly higher in
UB+ISO group as compared to control and ISO-treated samples (Fig 2.7B). These effects of UB
on MMP-2 expression were negated by pretreatment with a neutralizing anti-UB antibodies (Fig
2.7C). Treatment with rUB also enhanced ISO-mediated increases in MMP-2 expression (Fig
2.7D). However, the effects were observed at a higher concentration (100 µg/ml). MMP-9
expression tended to be higher in UB+ISO group when compared to sham (P=0.06; n=6; Fig
2.8A). ISO treatment had no effect on TIMP-2 protein levels. However, TIMP-2 protein levels
were significantly higher in UB+ISO samples when compared to control or ISO-treated samples
(Fig 2.8B).
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Figure 2.7. Expression and Activity of MMP-2 in Cardiac Fibroblasts. A & B) Cardiac
fibroblasts were pretreated with UB (10 µg/ml) for 30 min followed by treatment with ISO (10
µM) for 48 h. A) Cell lysates (20 µg) were analyzed by western using anti-MMP-2 antibodies.
*P<0.05 versus control (CTL); #P<0.05 versus ISO; n = 11. B) Concentrated conditioned media
(2 µg) were analyzed by gelatin in-gel zymography. *<0.01 versus CTL; #P<0.05 versus ISO; n
= 3. C) Cells were pretreated with neutralizing anti-UB antibody (Ab) for 30 min followed by
treatment with UB for 30 min. The cells were then treated with ISO for 48 h. Cell lysates (20 µg)
were analyzed by western using anti-MMP-2 antibodies. *P<0.05 versus CTL; $P<0.05 versus
UB+ISO; n=3. D) Cells were pretreated with rUB (10 or 100 µg/ml) for 30 min followed by
treatment with ISO for 48 h. Cell lysates (20 µg) were analyzed by western using anti-MMP-2
antibodies. *P<0.05 versus CTL; #P<0.05 versus ISO; n=3. Actin immunostaining indicates
protein loading.
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Figure 2.8. Expression of MMP-9 and TIMP-2. Cardiac fibroblast were pretreated with UB (10
µg/ml) for 30 min followed by treatment with ISO (10 µM) for 48 h. Cell lysates (20 µg) were
analyzed by western blot using anti-MMP-9 or anti-TIMP-2 antibodies. Actin immunostaining
indicates protein loading. A) Expression of MMP-9. #P=0.06 versus ISO; n = 6. B) Expression of
TIMP-2. *P<0.05 versus CTL; #P<0.05 versus ISO; n = 3-4.

UB Activates Akt, and Inhibition of Akt Inhibits MMP-2 Expression in Cardiac Fibroblast
To investigate if UB alone or in combination with ISO activates Akt, cardiac fibroblasts
were pretreated with UB followed by treatment with ISO for 15 min. Analysis of cell lysates
using phospho-specific antibodies showed that UB or ISO alone had no effect on Akt activation.
However, UB in the presence of ISO significantly increased Akt activity as compared to control
or ISO-treated samples (Fig 2.9A). MMP-2 activation is shown to be dependent on activation of
Akt in the heart (45). Inhibition of Akt using MK-2206 (18; 37) significantly inhibited UB+ISOmediated increases in MMP-2 expression (fold change vs CTL; UB+ISO, 1.71±0.1*;
MK+UB+ISO, 1.23±0.2#; MK, 0.59±0.3*; *P<0.05 vs Sham; #P<0.05 vs UB+ISO; n = 5; Fig
2.9B).
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Figure 2.9. Activation of Akt and its Role in MMP-2 Expression. Cardiac fibroblast were
pretreated with UB (10 µg/ml) for 30 min followed by treatment with ISO (10 µM) for 15 min to
measure Akt activation (A). To measure MMP-2 expression, cardiac fibroblasts were pretreated
with MK-2206 (MK; 1 μM) for 30 min, then with UB (10 µg/ml) for 30 min followed by
treatment with ISO (10 μM) for 48 h (B). Cell lysates (20 µg), were analyzed by western blot
using phospho-specific anti-Akt (serine-473) or anti-MMP-2 antibodies. The lower panels
exhibit mean data normalized to total Akt or actin. A) Phosphorylation (activation) of Akt.
*P<0.05 versus CTL; #P<0.05 versus ISO; n = 5. B) Expression of MMP-2. *P<0.05 versus
CTL; #P<0.05 versus UB+ISO; n = 5.

Discussion
Previously, we have provided evidence that β-AR stimulation increases levels of
extracellular UB and treatment with UB plays a protective role in β-AR-stimulated apoptosis in
ARVMs (44). This is the first study investigating the role of exogenous UB in the heart,
specifically in response to chronic β-AR stimulation. Here we confirm our previous finding of an
anti-apoptotic function for UB in vivo, and show that UB plays an important role in β-ARstimulated myocardial remodeling with effects on left ventricular function, fibrosis, and myocyte
apoptosis. UB infusion enhanced serum UB levels. Exogenous UB depressed β-AR-stimulated
increases in systolic and diastolic functional parameters of the heart. Increase in cardiac myocyte
apoptosis and myocardial fibrosis was significantly lower in the presence of exogenous UB.
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Exogenous UB enhanced activation of anti-apoptotic kinase Akt, while decreasing the activation
of pro-apoptotic kinases, GSK-3β and JNKs. It increased protein levels of MMP-2, MMP-9 and
TIMP-2 in the presence of ISO. In isolated cardiac fibroblast, UB enhanced expression of MMP2 and TIMP-2. It activated Akt and inhibition of Akt decreased MMP-2 expression.
Sympathetic nerve activity increases in the heart during cardiac failure. Prolonged
stimulation of the β-adrenergic neurohormonal axis contributes to the progression of heart failure
and mortality in animal models and human patients (3; 13). Catecholamines, released during
heightened adrenergic drive, accumulate in the interstitial space of the heart (6; 8). This
accumulation of catecholamines may contribute to left ventricular dysfunction (10). UB is a
normal constituent of plasma or serum (11; 29; 47). Levels of UB increase in plasma or serum of
patients under a variety of pathological conditions (26). However, the role of plasma UB in the
heart has not yet been investigated. Previously, we have shown that β-AR stimulation increases
extracellular levels of UB in ARVMs (44). Here we observed basal presence of UB in the serum
of ICR mice. Infusion of UB enhanced serum UB levels in the presence or absence of β-AR
stimulation. It was interesting to note that serum UB levels were lower in the presence of β-AR
stimulation, and β-AR stimulation alone had no effect on serum UB levels. These observations
suggest the possibility that β-AR stimulation may enhance UB absorption in vivo. Isoproterenol
is shown to increase cardiac output without affecting renal blood flow in dog, human, and lamb
(5; 40). However, the possibility of increased renal blood flow and renal clearance of UB in the
presence of isoproterenol cannot be ruled out. A significant finding of this study is that
exogenous UB has the potential to play an important role in the remodeling process of the heart
by affecting β-AR-stimulated increases in myocyte apoptosis and myocardial fibrosis.
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Ventricular hypertrophy is considered as an important compensatory mechanism that
allows the heart to maintain its output. Chronic β-AR-stimulation is shown to induce
hypertrophy, and increase heart rate and LV systolic function (20; 49; 50). Indicators of
hypertrophy such as HW/BW ratio, and myocyte cross-sectional area were increased to a similar
extent in both ISO-groups. Interesting finding of this study is that exogenous UB in the presence
of ISO restored systolic function to normal levels as indicated by decreased %FS, %EF and Vcf.
It partially restored ISO-mediated decrease in IVRT, IVCT, and ET. Changes in heart rate are
suggested to affect echocardiographic parameters in mice (52). As observed previously (23),
ISO-infusion increased heart rate in ICR mice. UB alone or in the presence of ISO had no effect
on basal or ISO-mediated increases in heart rates. Therefore, the observed changes in
echocardiographic parameters between ISO and UB+ISO groups may not be due to the changes
in heart rate. Extracellular UB is shown to promote intracellular Ca++ flux and reduce cAMP
levels through a G protein-coupled receptor in THP1 cells (41). Therefore, UB may affect
systolic and diastolic parameters of the heart by modulating levels of intracellular Ca++ and/or
cAMP. However, further investigations are needed to understand the mechanism by which
exogenous UB modulates heart function in the presence of β-AR agonist.
Cardiac myocyte apoptosis plays a crucial role in the pathogenesis of heart failure (17;
21; 33). β-AR-stimulated activation of JNKs and GSK-3β plays a pro-apoptotic role via the
involvement of mitochondrial death pathway (30; 39). Previously, UB is shown to activate PI3kinase and inhibit β-AR-stimulated activation of JNKs and GSK-3β, and mitochondrial death
pathway of apoptosis (44). PI3-kinase is an upstream activator of Akt (35), while Akt acts upstream
in the inactivation of GSK-3β (16). Active GSK-3β may act upstream in the activation of JNKs
(44). Here we show exogenous UB enhances β-AR stimulated activation of Akt, while inhibiting
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activation of GSK-3β and JNKs. These in vivo data confirm our previous in vitro findings, and
suggest that activation of PI3-Kinase/Akt pathway may be a mechanism involved in anti-apoptotic
effects of exogenous UB.
Chronic sympathetic stimulation is shown to induce growth of interstitial tissue in the
heart leading to fibrosis (7). MMPs and TIMPs play an important role in the remodeling of
extracellular matrix (46). Previously, we have shown that chronic β-AR stimulation increases
myocardial fibrosis (23). Consistent with these observations, we observed increased fibrosis
following chronic β-AR stimulation in ICR mice. The new finding of this study is that
exogenous UB inhibits chronic β-AR-stimulated increases in myocardial fibrosis. It enhanced
chronic β-AR-stimulated increases in the expression and activity of MMP-2. It also increased
expression of MMP-9 and TIMP-2 in the heart. Use of isolated adult cardiac fibroblasts
confirmed our in vivo findings with respect to the expression of MMPs and TIMP-2 in response
to UB. Of note, a higher concentration of rUB (as compared to bovine UB) was required to
observe increased expression of MMP-2 in the presence of isoproterenol in fibroblasts (Fig
2.7D). The reasons may include differential modification of UB from different sources. UB is
shown to be modified by acetylation of lysines, oxidation of methionine, and nitration of tyrosine
(25; 54). These modifications may influence interaction of extracellular UB with its receptor
and/or other proteins. The concentration of TIMP-2 is suggested to determine the role of TIMP-2
in activation of MMP-2. At low concentrations, TIMP-2 may activate MMP-2 on the cell surface
with the MT1-MMP-TIMP-2 complex serving as a receptor for proMMP-2, whereas at higher
concentrations, TIMP-2 may neutralize MT1-MMP and prevent activation of MMP-2 (24). The
data presented here suggest that exogenous UB decreases chronic β-AR-stimulated myocardial
fibrosis by modulating expression of MMPs and TIMP-2. Previously, we have reported that
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chronic β-AR stimulation increases MMP-9 expression in the heart (23). Here we did not
observe increased expression of MMP-9 in response to chronic β-AR stimulation. The observed
discrepant findings may relate to the use of different mouse strains. Previous study used
129xblack Swiss mice, while the current study uses ICR mice.
Increased MMP-2 expression is suggested to be dependent on Akt activation in the rat
heart during ischemia/reperfusion (45). In the current study, UB enhanced Akt activation in the
heart and in isolated cardiac fibroblasts in the presence of β-AR stimulation. Inhibition of Akt
decreased UB+ISO-mediated increases in MMP-2 expression. These data suggest a potential
relationship between Akt activation in response to UB treatment and MMP-2 expression in the
heart.

Perspective
The data presented here are novel and of significant interest since exogenous UB
modulates β-AR-stimulated myocardial function, and inhibits myocardial fibrosis and cardiac
myocyte apoptosis. The structural changes related to cardiac myocyte apoptosis and extracellular
matrix play a significant role in modulation of myocardial function and in the progression to
heart failure. Therefore, elucidation of processes that can shift the balance from myocyte
apoptosis to survival may have clinical implications. In addition, analysis of components of
extracellular matrix, including collagen type I and IV, laminin, fibronectin etc, may provide
insight into the modulation of heart function in the presence of exogenous UB. It should be
emphasized that our data on heart function and signaling are obtained seven days after ISOinfusion. The experimental time-point should be extended beyond seven days to investigate longterm effects of exogenous UB.
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Abstract
Stimulation of β-adrenergic receptor (β-AR) increases extracellular levels of ubiquitin (UB), and
exogenous UB plays an important role in β-AR-stimulated myocardial remodeling with effects
on LV function, fibrosis and myocyte apoptosis. Cardiac fibroblasts play a critical role in
maintaining the normal function of the heart, and in the reparative and fibrosis processes during
pathological cardiac remodeling. This study investigated the role of extracellular UB on cardiac
fibroblast function and phenotype, and involvement of CXCR-4 receptor (a potential receptor for
extracellular UB) in UB-mediated modulation of fibroblast function and phenotype. Using
primary cultures of adult rat cardiac fibroblasts, we provide evidence that extracellular UB
interacts with the cell surface. Extracellular UB induced rearrangement of fibrillar actin into the
formation of stress fibers as analyzed by phalloidin-FITC and α-smooth muscle actin (α-SMA, a
marker for transdifferentiation of fibroblasts into myofibroblasts) staining. However, it inhibited
the formation of lamellopodia and filopodia. Western blot analysis revealed increased expression
of α-SMA in response to extracellular UB. Extracellular UB co-immunoprecipitated with
CXCR-4 receptor. Proximity ligation assay confirmed interaction of extracellular UB with
CXCR-4. Extracellular UB inhibited the migration of cells into the wound. It activated ERK1/2,
while it had no effect on the activation of Akt. It increased the expression of vascular endothelial
growth factor A (VEGF-A), while decreasing the expression of β3 integrins. Most of the effects
of extracellular UB were negated by pretreatment with AMD-3100. Two UB mutants (mUB V70
and mUB F4), unable to interact with CXCR-4, had no effect on the expression of VEGF-A and
β3 integrins. Thus, extracellular UB, at least in part acting via the CXCR-4 receptor, plays an
important role in modulation of fibroblast function and phenotype.
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Introduction
Ubiquitin (UB), a highly conserved protein of ~8.5 kDa, is found in all eukaryotic cells.
The most important intracellular function of UB is to regulate protein turnover by the ubiquitinproteasome pathway (16). The ubiquitin-proteasome pathway may regulate receptor
internalization, hypertrophic response, apoptosis, and tolerance to ischemia and reperfusion in
cardiac myocytes (56). UB is a normal constituent of plasma. Elevated levels of UB are
described in the serum or plasma of patients with parasitic and allergic diseases (3), alcoholic
liver disease (47), type 2 diabetes (1), β2-Microglobulin amyloidosis (35) and chronic
hemodialysis patients (2). Patients with traumatic brain injury are shown to have increased UB
levels in the cerebrospinal fluid (27). Extracellular UB is proposed to have pleiotropic functions
including regulation of immune response, anti-inflammatory and neuroprotective activities (26;
28; 36), as well as regulation of growth and apoptosis in hematopoetic cells (10). Previously our
lab has shown that β-adrenergic receptor (β-AR) stimulation increases extracellular levels of UB,
and treatment of adult rat ventricular myocytes with UB inhibits β-AR-stimulated apoptosis (41).
In vivo, exogenous UB decreased β-AR-stimulated increases in cardiac myocyte apoptosis and
myocardial fibrosis (11).
The G protein–coupled receptor CXC chemokine receptor (CXCR)-4 is abundantly
expressed in immune cells and tissues, including cardiac fibroblast (21). CXCR-4 plays an
important role in a variety of biological processes, and is suggested to be involved in the
pathophysiology of various disease processes, such as cancer, HIV, ischemic myocardial injury,
and angiogenesis (49). Stromal derived factor-1α (SDF-1α) is the cognate ligand for CXCR-4
which is implicated in homing of hematopoietic stem cells during wound repair (7). SDF-1α is
shown to have cardioprotective effects against ischemia/reperfusion injury by promoting anti-
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apoptotic program (21). Interestingly, CXCR-4 has been identified as a receptor for UB in THP1
leukemia cell line (38). Using C-terminal truncated ubiquitin and ubiquitin mutants, Saini et al.,
provide evidence that the ubiquitin-CXCR-4 interaction follows a two-site binding mechanism in
which the hydrophobic surfaces surrounding Phe-4 and Val-70 are important for receptor
binding, whereas the flexible C terminus facilitates receptor activation (39). Recently, we
provided evidence that extracellular UB, acting via CXCR-4 receptor, increases expression of
angiogenic molecules and stimulates angiogenesis in cardiac microvascular endothelial cells
(45).
Cardiac fibroblast play a critical role in maintaining the normal function of the heart, and in
the remodeling process of the heart that occurs in response to myocardial infarction,
hypertension and heart failure (42). The objective of this study was to investigate the role of
extracellular UB on cardiac fibroblast phenotype and function, and to define the role of CXCR-4
receptor in modulation of fibroblast phenotype and function in response to extracellular UB. The
data presented here suggest that extracellular UB interacts with fibroblasts and CXCR-4
receptor, induces cytoskeletal reorganization, induces intracellular signaling, and inhibits
migration of cells into the wound. Most of these effects of UB are inhibited by CXCR-4 receptor
antagonist. The data presented here also suggest that extracellular UB and SDF-1α may elicit
different signaling mechanisms.

Materials and Methods
Vertebrate Animals
All experiments and procedures were reviewed and approved by the East Tennessee State
University Institutional Committee on Animal Care and conform to the Guide for the Care and

62

Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication
No. 85-23, revised 1996). Male Sprague-Dawley rats (average wt: 200-225g; Harlan,
Indianapolis, IN) were used for isolation of resident cardiac fibroblast cells. Rats were
anesthetized using a mixture of isoflurane (2.5%) and oxygen (0.5 l/min), and the heart was
excised following a bilateral cut in the diaphragm. Animals were euthanized by exsanguinations.

Fibroblast Isolation and Treatment
Adult rat cardiac fibroblasts were isolated as described (54). The cells were grown to
confluence and serum-starved for 48 h before use. Experiments were performed using first and
second passage cells. The cells were pretreated with AMD 3100 (10 µM; Sigma) or PD98059
(15μM; Calbiochem) for 30 min followed by treatment with UB (10 µg/ml; Sigma), biotin-UB
(500 ng/ml; Boston Biochem), mutated UB (mUB V70 and mUB F4; 10μg/ml; Boston Biochem)
or SDF-1α (1nM; Peprotech) for indicated time points. To investigate cellular interaction of UB,
cells were treated with FITC-UB (500 ng/ml; Boston Biochem) for 30 min.

Immunocytochemical Analysis
Immunocytochemical analysis was carried out as described (31). Briefly, isolated cardiac
fibroblast were plated on coverslips, fixed in 3.7% formaldehyde and permeabilized using 0.2%
Triton X-100. Coverslips were incubated in anti-α-SMA (1:500; Sigma) antibodies in 1% BSA
followed by Alexa Fluor-conjugated (1:500; Invitrogen) secondary antibodies. The coverslips
were then counterstained with Hoechst 33258, mounted and visualized using a fluorescent
microscope.
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Actin Polymerization Assay
Serum starved confluent cultures of cardiac fibroblast were treated with UB for 24 h.
Cells were washed twice with PBS, fixed in 3.7% formaldehyde solution, and permeabilized
with 0.2% Triton X-100. Nonspecific binding was blocked by incubating slides for 20 min at
room temperature in blocking solution (1% BSA in PBS). Cells were stained with PhalloidinFITC (1U/slide in blocking solution; Sigma-Aldrich, St. Louis, MO) for 20 min at room
temperature in the dark. After washing, the slides were mounted with SlowFade (Invitrogen
Corp., Carlsbad, CA) and visualized under fluorescent microscope using a rhodamine filter.
Images were acquired using a Nikon TE-2000 microscope with a Retiga-1300 color cooled
camera.

Co-immunoprecipitation Assay
Total cell lysates (300 µg proteins) were incubated overnight at 4°C with 3 µg of antiCXCR-4 (Abcam) antibody in 500 µl of TNT buffer (20 mM Tris·HCl, pH 7.5, 137 mM NaCl,
20 mM NaF, 5 mM EDTA, 1 mM PMSF, 10 mM sodium pyrophosphate, 0.2 M sodium
orthovanadate, 8 µg/ml aprotinin and 2 μg/ ml leupeptin, digitonin 0.05%, and 1% Triton X100). Protein A/G beads (60 µl, Thermo Scientific, Rockford, IL) were added to the mixture and
incubated for an additional hour with rocking. The immunocomplexes were then washed six
times with cold PBS. The immunoprecipitated proteins were resolved by SDS-PAGE and
transferred to PVDF membranes. The membranes were then probed with anti-UB (Santa Cruz)
antibody as described for western blot analyses.
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DuoLink In Situ Proximity Ligation Assay
To detect the interaction between CXCR-4 and UB, in situ proximity ligation assay
(PLA) was performed using Duolink kit according to the manufacturer's protocol (Olink
Bioscience, Uppsala, Sweden). After fixing and permeabilization, the cells were incubated
overnight with anti-UB antibodies (monoclonal; Santa Cruz) and anti-CXCR-4 antibodies
(polyclonal; Abcam). The cells were washed with PBS and incubated with appropriate secondary
antibodies. After a ligation reaction at 37°C of the DNA chains directly coupled to the PLA
probes, the cells were mounted and detection of the amplified probe was performed using
fluorescent microscope.

Migration Assay
Movement of cells through a wound introduced in a cell monolayer was determined as
described (19). Briefly, cardiac fibroblasts were grown as a confluent monolayer. After cells
were made quiescent in serum free medium for 48 h, a wound was created in the center of the
cell monolayer by gentle removal of attached cells using a sterile plastic pipette tip. Cell debris
was removed by a PBS wash and images of the wound were acquired using a Nikon TE-2000
microscope with a Retiga-1300 color cooled camera. The cells were then incubated in serum-free
DMEM containing UB for 24 and 48 h. Images were again acquired using as described above.
The wound area was measured using Bioquant Image Analysis software (Bioquant Image
Analysis Corp., Nashville, TN). The ability of cells to migrate into the wound area was assessed
by comparing micrographs at time zero, 24 and 48 h along the wounded area. The percentage of
wound area recovered was calculated by dividing the wound area after 24 h or 48 h by the initial
wound area at time zero, multiplied by 100.
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Western Blot Analysis
Cell lysates were prepared using lysis buffer [10 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1 mM EGTA, 1 mM EDTA, 0.2 mM sodium orthovanadate, 0.5% Nonidet P-40, 1% Triton X100, and 1 mM PMSF]. Equal amounts of total proteins (20 µg from cell lysates) were resolved
on 10% SDS-polyacrylamide gels. The proteins were transferred onto PVDF membrane. The
blots were then probed with primary antibodies directed against p-Akt (1:1000; Cell Signaling
Tech.), p-ERK1/2 (1:2000; Cell Signaling Tech.), β3-integrin (1:1000; Santa Cruz), VEGF-A
(1:200; Santa Cruz), or α-SMA (1:20000; Sigma) and appropriate secondary antibodies.
Membranes were then stripped and probed with Akt, ERK1/2, actin (Chemicon) or GAPDH
(Santa Cruz) antibodies to normalize protein loading. Band intensities were quantified using
Kodak photo documentation system (Eastman Kodak Co.). To detect biotin-labelled UB, the
membranes were incubated overnight in extra-avidin peroxidase (Sigma; 1:2000 dilution in
TBST). The biotin-labelled UB was visualized using chemiluminescence reagents.

Statistical Analysis
Data are expressed as the mean  SEM. Data was analyzed using Student’s t test or a
one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test.
Probability (P) values of <0.05 were considered to be significant.

Results
Extracellular UB Interacts with Fibroblasts and Induces Cytoskeletal Reorganization
To investigate if extracellular UB interacts with cells, cells were treated with FITC-UB
for 30 min. As a negative control, cells were incubated with FITC-labeled secondary antibodies
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(1:500) for 30 min. Visualization of cells using fluorescent microscope showed clear staining of
cells with FITC-UB. No staining was observed in control cells or cells incubated with FITClabeled secondary antibodies (Fig 3.1).

Figure 3.1. Cellular Interaction of Extracellular UB. Cardiac fibroblasts were incubated with
FITC-UB (500 ng/ml) or FITC-labelled secondary antibodies (CTL-FITC) for 30 min. The cells
were visualized by fluorescent microscope and photographed. CTL, control.

The rearrangement of actin in fibroblast is one of the driving forces of migration into the
wound (23; 53). In anchorage dependent cells, like fibroblast, there are two distinct cytoskeletal
arrangements: the geodom (polygonal net) and stress fibers (13). To analyze the actin
cytoskeleton, fibroblasts were treated with UB for 24 h followed by Phalloidin-FITC staining.
This analysis showed the presence of geodoms in untreated cells (Fig 3.2A). UB treated cells
mostly showed absence of geodoms. UB treatment enhanced polymerization of actin into stress
fibers (yellow arrows). However, there was no presence of filamentous membrane projections
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called filopodia or lamellipodia in the UB-treated cells (Fig 3.2B). Similar observations were
made when fibroblasts were immunostained for α-smooth muscle actin (α-SMA; Fig 3.2 C&D).
Western blot analysis of cell lysates using anti-α-SMA antibodies showed increased expression
of α-SMA 48 h after UB treatment (Fig 3.2E).

Figure 3.2. Extracellular UB Induces Cytoskeleton Rearrangement, and Increases Expression of
α-Smooth Muscle Actin (α-SMA): A-D. Semi-confluent cultures of cardiac fibroblast were
treated with UB for 24 h. The cells were stained with Phalloidin-FITC or anti-α-smooth muscle
actin (α-SMA) antibodies and visualized using fluorescent microscope (20 or 40X). Panels A &
B depict representative images from CTL and UB-treated cells following Phalloidin-FITC
staining. The yellow arrows indicate bundles of actin filaments called stress fibers that are
required for the traction of the rear of the cells toward the leading edge during migration (B).
Panels C & D depict representative images from CTL and UB-treated cells following
immunocytochemical staining using anti-α-SMA antibodies. E. Western blot analysis of α-SMA.
Cells were treated with UB for 48 h. Cell lysates were analyzed by western using anti-α-SMA
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antibodies. The lower panel exhibits the mean data normalized with GAPDH. *P<0.05 vs control
(CTL); n=5.

UB Interacts with CXCR-4 Receptors
CXCR-4 is identified as a receptor for extracellular UB in THP-1 cells (38). Coimmunoprecipitation is considered a standard method to determine if two proteins of interest
form a complex. To investigate the interaction of UB with CXCR-4 receptor, fibroblasts were
treated with Biotin-UB for 30 min. Cell lysates were immunoprecipitated with anti-CXCR-4
antibody. The resultant immunoprecipitates were analyzed by western blots using extra-avidin
peroxidase to detect Biotin-UB. This analysis showed the presence of Biotin-UB in cell lysates
immunoprecipitated with anti-CXCR-4 antibodies (Fig 3.3A). Binding specificity of UB with
CXCR-4 receptor was next analyzed by pretreatment of cells with AMD-3100 (CXCR-4
antagonist) or SDF-1α (a known ligand for CXCR-4 receptor) for 30 min followed by treatment
of cells with Biotin-UB for different time points (15 min, 3 h and 24 h). Western blot analysis of
cell lysates using extra-avidin peroxidase showed that pretreatment with AMD-3100 almost
completely inhibits binding of Biotin-UB to the cells at all different time-points. SDF-1α also
decreased binding of Biotin-UB at all different time points. However, this inhibition was more
pronounced at 3 and 24 h (Fig 3.3B). Pretreatment with AMD3100 also inhibited binding of
FITC-UB to the cells (Fig 3.3C). To confirm interaction of UB with CXCR-4, we used a recently
developed commercial assay (Duolink) called proximity ligation assay (PLA). The PLA
identifies interactions between two proteins in their native form. This assay results in a
fluorescent signal in the form of a spot when the two proteins of interest are closer than 40nm.
The specificity of the assay was tested using single antibodies directed against UB and CXCR-4.
This assay showed a few positive spots for interaction of UB with CXCR-4 receptor in untreated
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cells. This may be due to the fact that endogenous UB can bind to CXCR-4 receptors on the
cytoplasmic side of the transmembrane protein (29). However, clear increase in the positive
signal for the interaction of UB with CXCR-4 was observed in cells treated with UB as indicated
by an increase in bright red fluorescent spots when compared to CTL (Fig 3.3D).

Figure 3.3. Interaction of UB with CXCR-4 Receptor: A. Fibroblast were treated with biotinlabeled UB (b-UB; 10 μg/ml) for 30 min. Cell lysates were immunoprecipitated with antiCXCR-4 antibodies. Immunoprecipitates were analyzed by western blot using extra-avidin
peroxidase. Unlabeled UB and b-UB served as negative and positive controls, respectively. B.
Cells were pretreated with AMD 3100 (AMD; 10 μm) or SDF-1α (SDF; 1 nM) for 30 min
followed by treatment with b-UB for 15 min, 3 h or 24 h. Cell lysates were analyzed by western
blot using extra-avidin peroxidase. C. Cells were pretreated with AMD for 30 min followed by
treatment with FITC-UB for 30 min. Cells were visualized using fluorescent microscope. D.
Fibroblast were treated with UB for 24 h. The cells were then used for PLA using anti-UB and
anti-CXCR-4 antibodies. Increased fluorescent red staining in UB-treated sample indicates
interaction of UB and CXCR-4.
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Extracellular UB Inhibits Migration of Fibroblast into the Wound
Fibroblasts play a key role in the normal healing process after injury (30). They migrate
into the wound site and proliferate, and play a significant role in the reconstitution and deposition
of fibrotic scar (14). They also play a significant role in the repair processes of the heart
following myocardial infarction (43; 55). To examine the functional effects of extracellular UB
on fibroblast cell migration, we used an in vitro migration (scratch) assay as previously described
(19). Migratory potential of fibroblasts into the wound was clearly present in the untreated cells
as observed by the decrease in the percent wound area recovered following 24 and 48 h after
incubation (Fig 3.4A). Interestingly, UB treatment significantly inhibited the percent wound area
recovered at both time points (24 h; CTL, 45 % vs UB, 14 %; 48 h; CTL, 64 % vs UB, 35 %;
n=5; Fig 3.3B&C). Pretreatment with AMD3100 significantly enhanced the migration of cells
into the wound at both time points (CTL, 45±3; UB, 14±4*; AMD+UB, 34±6$; AMD, 47±3; 24
h; CTL, 64±2; UB, 35±6*; AMD+UB, 59±5$; AMD, 63±5; 48 h; *P<0.05 vs CTL; $P<0.05 vs
UB; n=5; Fig 3.4B&C). AMD 3100 alone had no effect on the migration of cells into the wound.
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Figure 3.4. Extracellular UB Inhibits Migration of Cardiac Fibroblast: Confluent fibroblast
monolayers were wounded using a sterile pipette tip and pretreated with AMD followed by
treatment with UB for 24 or 48 h. The ability of cells to migrate into the wound was assessed
following 24 or 48 h after UB treatment. Panel A demonstrates the wound area at 0 and 48 h
after treatment. Wound healing was assessed by calculating percent of recovered wound area.
Panel B and C represents the mean data of percent wound area recovered 24 and 48 h after UB
treatment; *P<0.05 versus CTL; $P<0.05 versus UB; n = 5.

Activation of Intracellular Signals by Extracellular UB, and Involvement of CXCR-4 Receptor
A variety of growth factors activate ERK1/2 (52). UB treatment is also shown to activate
ERK1/2 in THP-1 cells (40). To analyze the activation ERK1/2 in cardiac fibroblasts and
involvement of CXCR-4 receptors, cells were treated with AMD3100 or PD98059 (a selective
inhibitor of ERK1/2 pathway) followed by treatment with UB for 15 min. Western blot analysis
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of cell lysates using phospho-specific anti-ERK1/2 antibodies showed increased phosphorylation
(activation) of ERK1/2 in response to UB. Pretreatment with PD98059 completely inhibited
activation of ERK1/2, while inhibition of ERK1/2 was only partial in the presence of AMD3100
(CTL, 1±0.01; UB, 4.73±0.8*; AMD+UB, 2.4±0.8*$; PD+UB$, 0.05±0.02; AMD, 0.93±0.38;
*P<0.05 vs CTL; $P<0.05 vs UB; n = 5; Fig 3.5A). Similar observations were made when cells
were treated with SDF-1α in the presence of AMD3100 or PD98059 (CTL, 1±0.01; SDF,
3.95±0.94*; AMD+SDF, 2.52±0.62*$; PD+SDF, 0.74±0.68$; AMD, 0.93±0.38; *P<0.05 vs
CTL; $P<0.05 vs SDF; n = 5; Fig 3.5B). AMD 3100 alone had no effect on the activation of
ERK1/2.
Previously, we have provided evidence that inhibition of PI3-kinase inhibits the
protective effects of UB in β-AR-stimulated apoptosis in ARVMs (41). PI3-kinase acts upstream
in the activation of Akt, and activation of Akt is generally considered as an anti-apoptotic signal
(22). Western blot analysis of cell lysates using phospho-specific anti-Akt antibodies showed no
significant increase in Akt phosphorylation in response to UB treatment. On the other hand,
SDF-1α increased Akt phosphorylation within 15 min. Pretreatment with AMD3100 inhibited
SDF-1α-mediated activation of Akt (CTL, 1.00±0.01; UB, 1.24±0.19; AMD+UB, 1.36±0.33;
SDF, 1.74±0.23*; AMD+SDF, 0.81±0.26$; AMD, 1.25±0.24; *P<0.05 vs CTL; $P<0.05 vs SDF;
n = 5, Fig 3.5C).
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Figure 3.5. UB Activates ERK1/2, not Akt: Serum starved confluent cultures of fibroblasts were
pretreated with AMD, or PD98059 (PD; 15 μM) for 30 min followed by treatment with UB or
SDF-1a (SDF) for 15 min. Cell lysates were analyzed by western blot using phospho-specific
ERK1/2 or Akt (serine-473) antibodies. The lower panels exhibit mean data normalized to total
ERK1/2 or Akt. Both UB and SDF increased activation of ERK1/2; *P<0.05 versus CTL,
$
P<0.05 versus UB, n = 6 (A); *P<0.05 versus CTL; #P<0.01 versus SDF, n = 4-7 (B); *P<0.05
versus CTL, $P<0.05 versus SDF, n = 4-6 (C).
Extracellular UB Affects Expression of β3-intergrin and VEGF-A
Integrins provide linkages between ECM proteins and the actin cytoskeleton, thereby
providing adhesion of cells to the substratum and playing a crucial role in cell migration (20; 50).
Cardiac fibroblasts predominantly express β3 integrins (5). Western blot analysis of cell lysates
using anti-β3-integrin antibodies showed a significant decrease in the expression of β3 integrin
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in UB-treated (24 h) cells compared to CTL (Fig 3.6A). AMD3100 alone had no significant
effect on β3 integrin expression. However, pretreatment with AMD3100 almost completely
inhibited UB-mediated decrease in the expression of β3 integrin (CTL, 1.00±0.01; UB,
0.45±0.09*; AMD+UB, 0.99±0.22; AMD, 0.97±0.18; *P<0.05 vs CTL; n = 5; Fig 3.6A). The
UB-CXCR-4 interaction is suggested to involve the hydrophobic surfaces surrounding UB
residues Phe-4 and Val-70 (39). To further investigate the role CXCR-4 in β3 integrin
expression, cells were treated with two different mutated UBs; F4A and V70A. Western blot
analyses of cell lysates showed that these two mutations in the UB have no effect on β3 integrin
expression (Fig 3.6B).

Figure 3.6. UB Decreases β3-Intergrin Expression, and Mutated UBs (UBV70A and UBF4A)
have no Effect: Serum starved confluent cultures of fibroblasts were pretreated with AMD for 30
min followed by treatment with UB (10 µg/ml) for 24 h (A). The cells were also treated with
mutated UBs (UBV70A and UBF4A) for 24 h (B). Cell lysates were analyzed by western blot
using anti-β3-integrin antibodies. The lower panels exhibit the mean data normalized to actin.
*P<0.05 versus CTL; $P<0.05 versus UB; n = 6-7.

VEGF-A is suggested to play a role in tissue repair (12). Recently, we have shown that
extracellular UB increases VEGF-A expression in microvascular endothelial cells (45). Western
blot analysis of cell lysates using anti-VEGF-A antibodies showed a significant increase in the
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expression of VEGF-A in UB-treated (24 h) cells compared to CTL (Fig 3.7A). AMD3100 alone
had no significant effect on VEGF-A expression. However, it almost completely inhibited UBmediated increases in VEGF-A expression (CTL, 1.00±0.01; UB, 3.22±0.6; AMD+UB,
1.49±0.3, AMD, 1.15±0.1; *P<0.05 vs CTL; n = 5; 7A). Treatment of cells with mutated UBs
had no effect on VEGF-A expression (Fig 3.7B).

Figure 3.7. UB Increases VEGF-A Expression, while Mutated UBs (UBV70A and UBF4A) have
no Effect: Serum starved confluent cultures of fibroblasts were pretreated with AMD for 30 min
followed by treatment with UB (10 µg/ml) for 24 h (A). The cells were also treated with mutated
UBs (UBV70A and UBF4A) for 24 h (B). Cell lysates were analyzed by western blot using antiVEGF-A antibodies. The lower panels exhibit the mean data normalized to actin. *P<0.05 versus
CTL; $P<0.05 versus UB; n = 6.

Discussion
Cardiac fibroblasts play a critical role in maintaining normal function of the heart, and in
cardiac remodeling during pathological conditions, including hypertension and following
myocardial infarction (42). A major finding of this study is that extracellular UB modulates
fibroblasts phenotype and function. The data presented here shows that extracellular UB 1)
interacts with the cell surface; 2) induces cytoskeletal rearrangement; 3) inhibits migration of
fibroblasts into the wound and expression of β3 integrins; 4) activates intracellular signaling
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involving ERK1/2 pathway; 5) increases VEGF-A expression. Most of the effects of UB are
inhibited by the inhibition of CXCR-4 receptor, suggesting that involvement of CXCR-4 in
modulation of fibroblast function and phenotype in response to extracellular UB.

UB is a normal constituent in the plasma (47). Extracellular UB is proposed to have
pleiotropic functions including regulation of immune response, anti-inflammatory and
neuroprotective activities (26; 28; 36). Interaction and internalization of extracellular UB is
shown in human peripheral blood mononuclear cells and monocytic leukemia cells.
Inflammatory stimuli increase uptake of labelled UB suggesting the possibility that uptake of
extracellular UB could be directed towards restoring intracellular UB equilibrium (37).
Previously, using N-terminal biotin-labelled UB, we provided evidence for the cellular
interaction/uptake of extracellular UB in adult rat cardiac myocytes. β-AR stimulation enhanced
this interaction/uptake by ∼1.9-fold (41). This is the first study indicating interaction of
extracellular UB by cardiac fibroblasts. In THP-1 cells, extracellular UB is shown to induce
intracellular signaling, including phosphorylation of ERK1/2 and Akt (40). UB-mediated
phosphorylation of these kinases occurred transiently which declined within 30 min. However,
SDF-1a phosphorylation was sustained for 30 min. Furthermore, UB showed weaker
chemotactic activity in cell migration assay when compared to SDF-1α (40). In adult rat cardiac
myocytes, extracellular UB alone had no effect on the activation of JNKs and glycogen synthase
kinase-3β (GSK-3β). However, it inhibited β-AR-stimulated activation of JNKs and GSK-3β
(41). In cardiac fibroblasts, extracellular UB and SDF-1α activated ERK1/2. However, Akt
activation was only observed with SDF-1α. SDF-1α also binds to CXCR-7 (4). However,
overexpression of CXCR-7 in HEK293 failed to increase UB receptor binding, suggesting that
CXCR-7 may not serve as a receptor for extracellular UB (40). Collectively, these data suggest
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that the response to UB may be cell-type specific, and differential responses between UB and
SDF-1α could be due to the involvement of receptor/s other than CXCR-4.

Activated fibroblasts play a critical role in both the reparative and fibrotic processes. In
normal tissues, resident fibroblasts are quiescent, producing limited amounts of extracellular
matrix proteins and exhibiting few actin-associated cell-matrix and cell-cell contacts (48). Tissue
injury induces alterations in the microenvironment, resulting in differentiation of fibroblasts into
myofibroblasts (18). Myofibroblasts are characterized by the presence of microfilamentous
contractile apparatus enriched in α-SMA and its assembly into stress fibers (18). Formation of
stress fibers is important for fibroblast migration (8). Immunocytochemical analysis of cells
using phalloidin-FITC and α-SMA staining showed that intracellular UB induces structural
changes in the cardiac fibroblasts. UB treatment enhanced polymerization of actin into the stress
fibers. Extracellular UB also increased expression of α-SMA, a hallmark of differentiated
fibroblasts into myofibroblasts. However, it was interesting to note the absence of filamentous
membrane projections called filopodia or lamellipodia in UB-treated cells. UB-treated samples
also exhibited decreased migration of fibroblasts into the wound. This finding is in contrast to
cardiac microvascular endothelial cells where extracellular UB promotes the formation of stress
fibers, lamellopodia and filopodia (45). Previously, we have shown that exogenous UB decreases
β-AR-stimulated increases in myocardial fibrosis (11). UB-mediated decrease in the fibroblast
migration into the wound may help explain decreased fibrosis in the heart during β-AR
stimulated cardiac remodeling. However, further investigations are needed to prove this thesis.
Integrins are cell surface receptors that play a role in cell adhesion and migration, as well
as in growth and survival (20; 25). Fibroblasts are capable of modulating their microenvironment
through autocrine and paracrine signaling, thereby playing a role in tissue remodeling following
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tissue injury. Fibroblasts are also shown to play a role in the angiogenic process (32; 51).
Fibroblasts secrete fibroblast growth factor and VEGF-A (33). VEGF-A is considered as a potent
angiogenic inducer. In this study, we found that UB treatment increases VEGF-A expression.
Increased expression of VEGF-A is consistent with our previous finding in microvascular
endothelial cells where UB treatment increased VEGF-A expression (45). Cardiac fibroblasts
express β3 integrin (17). β3 integrin is shown to play a critical role in cardiac fibroblasts
adhesion, migration, proliferation and extracellular matrix production since β3-/- cardiac
fibroblast exhibit a significant reduction in these processes (5). The data presented here
demonstrates significant reduction in β3 integrin expression following UB treatment. The
absence of filopodia and lamellopodia, and decreased expression of β3 integrins can help explain
the reduced migration of fibroblasts into the wound in UB-treated samples. Increased expression
of VEGF-A may act as a paracrine factor for cardiac microvascular endothelial cells to induce
angiogenesis.
Recently, CXCR-4 has been identified as a receptor for extracellular UB in human
myeloid cells (38). SDF-1also calledCXCL-12) isconsidered a natural ligand for CXCR-4
(6). SDF-1α/CXCR-4 axis is suggested to play a pivotal role in the regulation of bone marrowderived stem cell homing, repopulation and mobilization of stem cells into the peripheral blood
(24). Mice lacking SDF-1α or CXCR-4 confirm the essential role of SDF-1α/CXCR-4 axis in
hematopoiesis, cardiogenesis and vasculogenesis during embryonic development (15; 34; 46;
57). Cardiac myocytes and non-myocyte cell populations of the heart express CXCR-4 receptors
(9). Previously, we provided evidence for CXCR-4 as a receptor for extracellular UB in
microvascular endothelial cells (44). Here, we provide evidence for CXCR-4 as a receptor for
extracellular UB in cardiac fibroblasts. We show that extracellular UB co-immunoprecipitates
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with CXCR-4. Interaction of extracellular UB with CXCR-4 was confirmed using the PLA
technique. AMD 3100 and SDF-1α time-dependently decreased interaction of extracellular UB
with CXCR-4 as analyzed by western blot. AMD3100 also decreased binding of FITC-labeled
UB. It enhanced the migration of cells in the wound area, decreased activation of ERK1/2 and
expression of VEGF-A and restored expression of β3 integrin. Use of two different mutated UB
proteins (F4A and V70A) on the expression of β3-integrin and VEGF-A further supports the
involvement of CXCR-4 receptor in extracellular UB signaling. It is interesting to note that
AMD 3100 almost completely inhibits UB-mediated increases in β3 integrins and VEGF-A
expression. However, inhibition of ERK1/2 was partial. The reasons for this differential response
may include differences in binding affinities for AMD 3100 and UB and/or incubation durations.
Perspectives
Cardiac fibroblasts are important in maintaining the normal function of the heart as well
as in wound repair following injury to the heart. UB is found in normal plasma. A variety of
disease states increase levels of UB in the plasma. Here we provide evidence that extracellular
UB modulates cardiac fibroblast function and phenotype via the involvement of CXCR-4
receptor. Further investigation of signaling mechanisms leading to UB-mediated regulation of
cardiac fibroblast function and phenotype may help uncover novel strategies to improve cardiac
remodeling and function.
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Abstract
Exogenous ubiquitin (UB) plays an important role in β-AR-stimulated myocardial remodeling
with effects on LV function, fibrosis and myocyte apoptosis. Extracellular UB modulates cardiac
fibroblast function and phenotype, and increases expression of angiogenic molecules in cardiac
microvascular endothelial cells. This study tested the hypothesis that exogenous UB plays a
protective role in ischemia/reperfusion (I/R) injury in the heart and cardiac myocytes. Isolated
mouse hearts underwent 15 min of baseline perfusion, 25 min of global ischemia and 40 min of
reperfusion. UB (10 μg/ml) was infused within 5 min before ischemia. Isolated adult rat
ventricular myocytes (ARVMs) were exposed to simulated ischemia/reperfusion by placing the
cells in a hypoxic chamber for 2.5 h followed by reoxygenation (H/R) for indicated time points.
Measurement of infarct size using TTC-staining showed that UB infusion significantly decreases
infarct size. UB I/R hearts showed a significant improvement in functional recovery as measured
by increased % left ventricular developed pressure. Activation of proapoptotic proteins, p-STAT1 and caspase-9, was significantly lower in UB I/R hearts when compared to I/R. In ARVMs,
apoptosis was lower in UB H/R group when compared to H/R. Activation of Akt was higher,
activation of GSK-3β was lower in UB H/R cells versus H/R. The number of reactive oxygen
species and superoxide positive ARVMs was lower in UB-treated samples. TMRM staining
showed that UB treatment increases the number of ARVMs with polarized mitochondria.
CXCR-4 antagonist (AMD3100) significantly negated the protective effects of UB on H/Rinduced apoptosis and activation of Akt and GSK-3β. UB mutants, unable to bind to CXCR-4,
had no effect on H/R-induced apoptosis, activation of Akt and GSK-3β and oxidative stress.
Thus, exogenous UB, most likely acting via CXCR-4, plays a protective role in I/R injury with
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effects on infarct size, heart function, cardiac myocyte apoptosis, ROS and intracellular
signaling.
Introduction
Myocardial ischemia/reperfusion (I/R) injury occurs from reperfusion of blood and oxygen
in acute myocardial infarction. I/R injury increases reactive oxygen species (ROS) production
and induces cardiac myocyte apoptosis (25; 27; 55). The apoptotic pathway involves
mitochondrial dysfunction, which is activated in myocytes by hypoxia, ischemia/reperfusion, and
oxidative stress (9). Mitochondria are considered as a major source of ROS and an increase in
ROS causes mitochondrial dysfunction including a loss in mitochondrial membrane potential
(24; 28). Mitochondrial dysfunction is a major contributor to loss of myocytes during myocardial
ischemia and subsequent reperfusion (42). Despite advances in understanding the molecular and
cellular mechanisms that regulate the damage caused by I/R injury, the treatment for I/R injury
remains a challenge.
Ubiquitin (UB), a highly conserved protein of ~8.5 kDa, is found in all eukaryotic cells.
The most important intracellular function of UB is to regulate protein turnover by the ubiquitinproteasome pathway (17). The ubiquitin-proteasome pathway may regulate receptor
internalization, hypertrophic response, apoptosis, and tolerance to ischemia and reperfusion in
cardiac myocytes (61). UB is a normal constituent of plasma. Elevated levels of UB are
described in the serum or plasma of patients with parasitic and allergic diseases (4), alcoholic
liver disease (54), type 2 diabetes (2), β2-Microglobulin amyloidosis (41) and chronic
hemodialysis patients (3). Patients with traumatic brain injury are shown to have increased UB
levels in the cerebrospinal fluid (37). Extracellular UB is proposed to have pleiotropic functions
including regulation of immune response, anti-inflammatory and neuroprotective activities (36;
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38; 43), as well as regulation of growth and apoptosis in hematopoetic cells (11). C-X-C
chemokine receptor (CXCR-4) plays an important role in a variety of biological processes, and is
suggested to be involved in the pathophysiology of various disease processes, such as cancer,
HIV, ischemic myocardial injury, and angiogenesis (56). Stromal derived factor-1α (SDF-1α) is
the cognate ligand for CXCR-4 which is implicated in homing of hematopoietic stem cells
during wound repair (8). Interestingly, CXCR-4 has been identified as a receptor for UB in
THP1 leukemia cell line (46). Using C-terminal truncated ubiquitin and ubiquitin mutants, Saini
et al., provide evidence that the ubiquitin-CXCR-4 interaction follows a two-site binding
mechanism in which the hydrophobic surfaces surrounding Phe-4 and Val-70 are important for
receptor binding, whereas the flexible C terminus facilitates receptor activation (47).
Previously our lab has shown that β-adrenergic receptor (β-AR) stimulation increases
extracellular levels of UB, and treatment of adult rat ventricular myocytes with UB inhibits βAR-stimulated apoptosis (49). In vivo, exogenous UB decreased β-AR-stimulated increases in
cardiac myocyte apoptosis and myocardial fibrosis (12). Our recent work suggest that
extracellular UB modulates cardiac fibroblast function and phenotype (unpublished work), and
increases expression of angiogenic molecules in cardiac microvascular endothelial cells (51).
The objective of this study was to investigate the role extracellular UB plays in I/R injury in
isolated hearts and cardiac myocytes. The data presented here suggest that extracellular UB
decreases infarct size, improves functional recovery of the heart, and decreases activation of
STAT-1 and caspase-9. In ARVMs, UB treatment decreased H/R-induced myocyte apoptosis,
activated Akt while inactivating GSK-3β, decreased oxidative stress and improved the number of
myocytes with polarized mitochondria. Most of these effects of UB are negated by CXCR-4
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antagonist AMD 3100. Mutated UB, unable to bind CXCR-4 had no effect on H/R-induced
apoptosis, intracellular signaling or oxidative stress.

Methods and Materials
Vertebrate Animals
All experiments and procedures were reviewed and approved by the East Tennessee State
University Institutional Committee on Animal Care and conform to the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication
No. 85-23, revised 1996). Male C57BL/6 mice (8 to 10 week-old; Jackson Laboratories, Bar
Harbor, ME) were used. Mice were anesthetized using a mixture of isoflurane (2.5%) and
oxygen (0.5 l/min) and the heart was excised following a bilateral cut in the diaphragm. Animals
were euthanized by exsanguinations.

Isolated Heart Perfusion System (Langendorff)
Langendorff global I/R experiments were performed in isolated mouse hearts as
previously described (29). The aorta was quickly cannulated and the heart was perfused using
Krebs buffer containing (in mM): 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 24.8 NaCHO3,
2.5 CaCl2, and 10.6 glucose. The buffer was equilibrated with 95% O2 and 5% CO2 and
maintained at 37°C. A fluid-filled silicon balloon was inserted in the left ventricle through the
mitral valve for left ventricular developed pressure (LVDP) measurement with a pressure
transducer (AD Instruments, Dunedin, New Zealand). Hearts were allowed to stabilize during a
15 min baseline period followed by 25 min ischemia and 40 min reperfusion. UB (10 μg/ml in
Krebs buffer) treatment was started within 5 min before ischemia. I/R hearts received Krebs
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buffer throughout the procedure. Immediately at the end of reperfusion, hearts were snap frozen
with liquid nitrogen and stored at -80ºC.

Infarct Size
Infarct size was measured using tetrazolium chloride (TTC; Sigma) staining. Each heart
was sliced transversely to yield five slices. The slices were incubated in 1% TTC for 15 min at
37°C. Infarct size was calculated, using Bioquant image analysis software, as the percentage of
total white area divided by the total tissue area.

Cardiac Myocyte Isolation, Treatment and Hypoxia/Reoxygenation
Calcium-tolerant ARVMs were isolated from the hearts of adult male Sprague-Dawley
rats (150-200 g) as described previously (39). ARVMs were plated in Dulbecco’s modified
Eagle’s medium (DMEM; Mediatech) supplemented with 25 mM HEPES, 0.2% albumin, 5 mM
creatine, 2 mM L-carnitine, 5 mM taurine, and 0.1% penicillin-streptomycin at a density of 30–
50 cells/mm2 on 100-mm tissue culture dishes or coverslips (Fisher Scientific) precoated with
laminin (1 µg/cm2). ARVMs were cultured overnight in the above medium. After changing the
medium, the ARVMs were treated with UB (10 µg/ml; Sigma) or mutated UB (mUB V70 and
mUB F4; 10μg/ml; Boston Biochem) for 30 min at 370C with 5% CO2. To simulate
ischemia/reperfusion, ARVMs were incubated at 37°C with 5% CO2 and 0.1% O2 in a hypoxia
chamber (Pro-Ox Model C21, BioSpherix Ltd, Redfield NY) for 2.5 h. After changing the media
containing the corresponding treatments, ARVMs were then incubated at 370C with 5% CO2
(reoxygenation) for indicated time points. To investigate the role of CXCR-4, cells were
pretreated with AMD 3100 for 30 min prior to UB treatment.
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Apoptosis
To detect apoptosis, myocytes were placed in a hypoxic chamber for 2.5 h, followed by
18 h of reoxygenation. TUNEL-staining assay was performed using in situ death detection kit
according to the manufacturer’s instructions (Roche Molecular Biochemicals). Hoechst 33258
(10 µM; Sigma, St Louis, MO) staining was used to count the total number of nuclei. The
percentage of TUNEL-positive cells (relative to total ARVMs) was determined by counting
∼200 cells in 10 randomly chosen fields per coverslip for each experiment.

Measurement of Mitochondrial Membrane Polarization
ARVMs were plated on 50-mm MatTek dishes (MatTek, Ashland, MA) and incubated
for 30 min in 3 ml of culture medium containing 200 nM TMRM at 37ºC and 5% CO2 (58). After
30 min of incubation, the culture media was substituted with PBS plus 5 mM glucose and 10 mM
succinate. Before imaging, a cover slip was placed over the cells, and 15 µl sterile oxyrase was
added. Oxyrase selectively removes oxygen creating depletion of oxygen in the myocyte’s
immediate surroundings. Images of cells were captured using the Zeiss AxioCam MRm
monochrome digital camera. The number of polarized cells (i.e., those exhibiting TMRM
fluorescence) was counted at each time point of oxyrase incubation and was expressed as a
percent of total cells before anoxia (basal) imaged using fluorescent microscopy.

ROS Detection
ROS was detected using the Total ROS detection kit from Enzo Life Sciences and used
according to manufacturer’s instructions. This kit is designed to directly monitor real time ROS
production in live cells using fluorescent microscopy. For this, UB or mutated UB treated cells
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were exposed to hypoxia 2.5 h followed by reoxygenation for 1 h. Cells were loaded with ROSresponsive fluorescence probe for 1 h during reoxygenation. After washing with phosphatebuffered saline (PBS), cells were visualized using a fluorescent microscope. Superoxide staining
appears as red dots, while ROS-positive cells exhibit green fluorescence.

Western Analysis
LV tissue lysates were prepared in RIPA buffer [10 mM Tris-HCl (pH 7.2), 158 mM
NaCl, 1 mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 1 mM sodium
orthovanadate, 0.2 mM phenylmethylsulfonyl fluoride] using a tissue homogenizer. Cell lysates
were prepared using lysis buffer [10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1 mM
EDTA, 0.2 mM sodium orthovanadate, 0.5% Nonidet P-40, 1% Triton X-100, and 1 mM
phenylmethylsulfonyl fluoride]. Equal amounts of total proteins (60 µg from tissue or cell
lysates) were resolved on 10% SDS-polyacrylamide gels. The proteins were transferred onto
PVDF membrane. The blots were then probed with primary antibodies directed against p-Akt
(1:1000; Cell Signaling Tech.), p-GSK-3β (1:1000; Cell Signaling Tech.), caspase-9 (1:1000;
Millipore), p-STAT-1 (1:1000; Millipore), and appropriate secondary antibodies. Membranes
were then stripped and probed with Akt, GSK-3β, STAT-1, or actin (Chemicon) antibodies to
normalize protein loading. Band intensities were quantified using Kodak photo documentation
system (Eastman Kodak Co.).
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Statistical Analysis
Data are expressed as the mean  SEM. Data was analyzed using Student’s t test or a
one-way analysis of variance (ANOVA) followed by the Student-Newman-Keuls test.
Probability (P) values of <0.05 were considered to be significant.

Results
UB Treatment Decreases I/R-induced Infarct Size and Improves Functional Recovery of the
Heart
To investigate if extracellular UB treatment modulates global I/R injury, isolated hearts
were subjected to 25 min of global ischemia followed by 40 min of reperfusion in the presence
or absence of UB. TTC staining showed a significant decrease in % infarct size in UB I/R hearts
when compared to I/R alone (I/R, 39.5±6.9; UB I/R, 13.7±2.8*; *p<0.05 vs I/R; n= 6; Fig 4.1A).
Left ventricular development pressure (LVDP) is a measure of cardiac performance in
langendorff perfused hearts. UB I/R hearts showed a greater increase in % LVDP recovery
following ischemia when compared to I/R hearts (I/R, 50.7±4.4; UB I/R, 67.3±4.3*; *p<0.05 vs
I/R; n= 6; Fig 4.1B).
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Figure 4.1. UB Decreases Infarct Size and Improves LVDP Recovery. Mouse hearts underwent
global ischemia for 25 min, followed by 40 min reperfusion. A. Upper panel depicts
representative tetrazolium chloride (TTC) stained hearts showing a decrease in infarcted region
(white area) in UB I/R hearts. The lower bar graph exhibits % infarct size. B. Recovery of left
ventricular developed pressure. *P<0.05 vs I/R; n = 6 hearts in each group.

UB Decreases Activation of p-STAT-1 and Caspase-9 in I/R Hearts
Proapoptotic proteins, STAT-1 and caspase-9, are activated during I/R injury (35; 52).
Western blot analysis of heart homogenate using anti-p-STAT-1 antibodies showed a significant
decrease in the phosphorylation of p-STAT in UB I/R group vs I/R (I/R, 0.90±0.11; UB I/R,
0.54±0.03*; *p<0.05 vs I/R; n= 4; Fig 4.2A). Presence of ~17 kDa band on western blot using
anti-caspase-9 antibodies indicates activation of caspase-9. Western blot analysis of heart
homogenate showed decreased levels of active caspase-9 in UB I/R group when compared to I/R
(I/R, 1.63±0.27; UB I/R, 0.89±0.08*; *p<0.05 vs I/R; n= 4; Fig 4.2B).
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Figure 4.2. UB Decreases I/R-Induced Activation of STAT-1 and Caspase-9: Total heart lysates
(60 µg) were analyzed by western blot using phospho-specific STAT-1 (A) or anti-caspase-9
antibodies (B). The lower panels exhibit mean data normalized to total STAT-1 or actin.
*P<0.05 versus I/R; n = 4.

UB Treatment Decreases Hypoxia/Reoxygenation-Induced Apoptosis in ARVMs
Hypoxia for 2.5 h followed by reoxygenation for 18 h (H/R) significantly increased
apoptosis when compared to control (CTL) cells incubated at 370C with 5% CO2 (regular
incubator). However, UB treated samples showed a significant decreases in TUNEL-positive
ARVMs when compared to H/R. Pretreatment with AMD 3100 significantly negated the
protective effects of UB (CTL, 3.3±0.7; H/R, 35.5±6.3*; UB H/R, 9.2±2.2&; AMD+UB H/R,
34.1±4.1*$; AMD H/R, 24.3±5.0*; *p<0.05 vs CTL; &p<0.05 vs H/R; &p<0.05 vs UB; n = 3-4;
Fig 4.3A). Mutated UB (mUBV70 or mUBF4) had no effect on H/R-mediated increases in the
number of apoptotic ARVMs (CTL, 2.2±0.2; H/R, 25.7±2.3*; mUBV70 H/R, 21.0±5.4*;
mUBF4 H/R, 21.5±2.6*; *p<0.05 vs CTL; n=3-4; Fig 4.3B).
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Figure 4.3. UB Inhibits H/R-Induced Apoptosis in ARVMs: A. ARVMs pretreated with AMD
3100 (AMD; 10 µM) for 30 min followed by treatment with UB (10 µg/ml) for 30 min. The cells
then underwent hypoxia for 2.5 h min and reoxygenation for 18 h. *p<0.05 vs CTL; &p<0.05 vs
H/R; &p<0.05 vs UB; n = 3-5. B. ARVMs were treated with mutated UBs (mUB V70 and mUB
F4; 10μg/ml) for 30 min followed by H/R as described. *P<0.05 versus CTL.
Activation of Akt and GSK-3β in ARVMs
PI3-kinase activates Akt, and activation of Akt plays an anti-apoptotic role (26). Western
blot analysis of cell lysates using phospho-specific anti-Akt antibodies showed a significant
increase in Akt phosphorylation (activation) in UB H/R group when compared to CTL and H/R
groups. AMD 3100 pretreatment significantly decreased UB H/R-mediated increase in Akt
phosphorylation (CTL, 1±0.01; H/R, 1.11±0.1; UB H/R, 2.23±0.3*; AMD+UB H/R, 1.06±0.2$;
*P<0.05 vs CTL and H/R; $P<0.05 vs UB H/R; n = 4-6; Fig 4.4A). Treatment with mutated UB
(mUBV70) had no effect on the phosphorylation of Akt (CTL, 1±0.01; H/R, 1.11±0.1; UB H/R,
2.23±0.3*; mUBV70, 1.09±0.1$; *P<0.05 vs CTL and H/R; $P<0.05 vs UB H/R; n = 4-6; Fig
4.4B).
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Figure 4.4. UB Activates Akt in ARVMs: A. ARVMs were pretreated with AMD 3100 (AMD;
10 µM) for 30 min followed by treatment with UB (10 µg/ml) for 30 min. The cells then
underwent hypoxia for 2.5 h and reoxygenation for 15 min. B. ARVMs were treated with
mutated UBs (mUB V70 and mUB F4; 10μg/ml) for 30 min followed by H/R for as described.
Cell lysates (20 µg) were analyzed by western using phospho-specific anti-Akt antibodies. The
lower panels exhibit mean data normalized to total Akt. *P<0.05 versus H/R; $P<0.05 versus UB
H/R; n = 4-5.
Phosphorylation of an NH2-terminal serine residue (Ser9) inactivates GSK-3β. Akt is one
of the upstream kinases involved in phosphorylation (Ser9) and inactivation of GSK-3β (22).
Western blot analysis of cell lysates using phospho-specific (Ser9) anti-GSK-3β antibodies
showed decrease phosphorylation (activation) of GSK-3β in UB H/R group when compared to
CTL and H/R groups. AMD 3100 pretreatment significantly decreased UB H/R-mediated
increase in Akt phosphorylation (CTL, 1.00±0.01; H/R, 1.23±0.2; UB H/R, 2.47±0.2*;
AMD+UB H/R$, 1.25±0.1; *P<0.05 vs CTL and H/R, $P<0.05 vs UB H/R; n = 4-6; Fig 4.5A).
Treatment with mutated UB (mUBV70) had no effect on the phosphorylation of Akt (CTL,
1±0.01; H/R, 1.23±0.2; UB H/R, 2.47±0.3*; mUBV70 H/R, 1.06±0.1$; *P<0.05 vs CTL and
H/R; $P<0.05 vs UB H/R; n = 4-6; Fig 4.5B).
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Figure 4.5. UB Inactivates GSK-3β in ARVMs: A. ARVMs were pretreated with AMD 3100
(AMD; 10 µM) for 30 min followed by treatment with UB (10 µg/ml) for 30 min. The cells then
underwent hypoxia for 2.5 h and reoxygenation for 15 min. B. ARVMs were treated with
mutated UBs (mUB V70 and mUB F4; 10μg/ml) for 30 min followed by H/R for as described.
Cell lysates (20 µg) were analyzed by western using phospho-specific anti-GSK-3β antibodies.
The lower panels exhibit mean data normalized to total GSK-3β. *P<0.05 versus H/R; $P<0.05
versus UB H/R; n = 4-5.

UB Treatment Decreases the Number of ROS and Superoxide-Positive Myocytes
ROS are implicated in ischemic or hypoxic-toxicity with and without reperfusion (1; 31).
To determine the effect UB on oxidative stress, we measured the number ROS and superoxide
positive ARVMs following H/R. H/R increased the number of ROS-positive ARVMs when
compared to CTL. The UB H/R group showed a significant decrease in total number of ROSpositive ARVMs when compared to H/R. However, mutated UBs showed no significant change
in total ROS when compared to H/R (CTL, 7.2±2.3; H/R, 54.2±7.3*; UB H/R, 11.6±2.6$;
mUBF4 H/R, 52.0±5.1*; mUBV70 H/R, 57.9±3.0*; p<0.05 vs CTL; $P<0.05 vs H/R; n = 4-6;
Fig 4.6).
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Figure 4.6. UB Decreases the Number of H/R-Induced ROS-Positive ARVMs: ARVMs were
pretreated with UB or mutated UBs (mUB V70 and mUB F4; 10μg/ml) for 30 min. The cells
then underwent hypoxia for 2.5 h followed by reoxygenation for 1 h. At time of reoxygenation,
cells were loaded with total ROS detection stain for 1 h. Green fluorescent staining indicates
ROS-positive ARVMs (A). B. Quantitative analysis of ROS-positive ARVMs. *P<0.05 versus
CTL; $P<0.05 versus UB H/R; n = 4-6.

Previous reports have shown an increase in superoxide after reperfusion of the isolated
ischemic heart (34; 59). Pretreatment with UB showed a significant decrease in superoxidepositive myocytes when compared to H/R myocytes. However, mutated UBs showed no change
in superoxide-positive ARVMs when compared to H/R (CTL, 5.6±1.3; H/R, 20.7±3.4*; UB H/R,
7.6±2.8$; mUBF4 H/R, 24.6±2.8*; mUBV70 H/R, 22.3±5.2*; *P<0.05 vs CTL; $P<0.05 vs H/R;
n = 4-6; Fig 4.7).
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Figure 4.7. UB Decreases the Number of H/R-Induced Superoxide-Positive ARVMs: ARVMs
were pretreated with UB or mutated UBs (mUB V70 and mUB F4; 10μg/ml) for 30 min. The
cells then underwent hypoxia for 2.5 h followed by reoxygenation for 1 h. At time of
reoxygenation, cells were loaded with superoxide detection stain for 1 h. Red fluorescent
staining indicates superoxide-positive ARVMs (A). B. Quantitative analysis of superoxidepositive ARVMs. *P<0.05 versus CTL; $P<0.05 versus UB H/R; n = 4-6.

UB Treatment Protects Mitochondrial Polarization
H/R induces mitochondrial damage, including loss of membrane potential (13). To
investigate if UB treatment protects mitochondrial polarization, ARVMs were subjected to
anoxia. Mitochondrial polarization was monitored with TMRM potentiometric dye for 105 min
under these conditions. We found a trend towards maintained mitochondrial polarization 60 min
after UB treatment. However, the number of ARVMs with polarized mitochondria was
significantly greater in UB-treated samples 105 min after UB treatment (Fig 4.8).
107

Figure 4.8. UB Treatment Helps Maintain Mitochondrial Membrane Polarization: ARVMs were
incubated with oxyrase to create anoxic conditions. Mitochondrial membrane polarization was
measured using TMRM loading. Upper panel depicts images of ARVMs obtained using
fluorescent microscope before anoxia (basal) and at indicated time points during anoxia. The
number of polarized cells (i.e., those exhibiting TMRM fluorescence) was counted at each time
point of oxyrase incubation and was expressed as a percent of total cells before anoxia (basal),
and are expressed as means ± SE (n = 6). *P<0.05 vs CTL.
Discussion
Previously, we provided evidence that β-AR stimulation increases levels of extracellular
UB and that treatment with UB plays a protective role in β-AR-stimulated apoptosis in ARVMs
(49). I/R injury induces cardiac myocyte apoptosis (18). A major finding of this study is that
extracellular UB plays a protective role in I/R-induced injury in the heart, and cardiac myocytes
apoptosis. The data presented here suggest that UB treatment decreases I/R-induced increases in
infarct size while improving functional recovery of the heart following ischemia. These changes
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in the heart associate with decreased activation of STAT-1 and caspase-9. In isolated ARVMs,
UB decreased H/R-induced apoptosis. It activated Akt and decreased the number of ROS- and
superoxide-positive ARVMs. UB treatment also helps maintain mitochondrial membrane
polarization under anoxic conditions. Most of the effects of UB were negated by inhibition of
CXCR-4 receptor, while mutated UB had no effect.
The primary pathological expression of coronary artery disease is myocardial injury
resulting from an I/R insult (45). Cardiac myocytes are highly aerobic cells, and almost all of
their energy production comes from oxidative phosphorylation under normal conditions (50). It
is clear that production of ROS during both ischemia and reperfusion is a major factor
contributing to I/R-induced cardiac injury (14; 15). Global I/R injury is known to cause
myocytes apoptosis and create an infarcted region (19). Here we show UB treatment decreased
infarct size in isolated hearts when compared to I/R treated hearts. UB treatment also improved
LVDP recovery after ischemia.
Previous studies have characterized a proapoptotic effect of STAT-1 by the upregulation
of caspase-1 and proapoptotic genes such as FAS, FAS ligand, p21, and p53 (7; 32). Increased
STAT-1 activation is reported to impair myocardial performance (23). Mitochondrial damage
and leakage of cytochrome c leads to the activation of caspase-9 (53). Caspase-9 is expressed at
high levels in the heart and is implicated in mitochondrial-mediated apoptosis (30). The
apoptotic cascade is initiated by mitochondrial damage and activation of caspase-9 (48).
Caspase-9 is activated during ischemia and remains activated throughout reperfusion in the intact
rat heart (48). Activated caspase-9 is detected ~ 17 kDa band on SDS-PAGE. Here, we show that
treatment with UB decreases the activation of STAT-1 and caspase-9. These data supports the
previous findings of activation of STAT-1 and caspase-9 during I/R injury, and suggest that UB-
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mediated decrease in the activation of these molecules may ultimately help preserve heart
function.
Apoptosis of cardiac myocytes is identified as an important process in the progression to
heart failure (57). Apoptosis contributes, with necrosis, to the cardiac cell loss after I/R injury
(48). Using isolated ARVMs, we provide evidence that UB decreases H/R-mediated increases in
the number of apoptotic ARVMs. Akt, a central regulator of myocyte survival, is shown to
protect myocytes against I/R injury in the mouse heart (16). Several upstream regulators are
reported to turn off the activity of GSK-3β, among those Akt is a well-characterized Ser/Thr
kinase phosphorylating GSK-3β. Akt phosphorylates GSK3β (Ser-9), and this residue lies in a
typical Akt consensus substrate motif (40). Previously, we have shown that activation of GSK-3β
plays a pro-apoptotic role in β-AR-stimulated cardiac myocyte apoptosis (39). Exogenous UB
inhibited β-AR-stimulated activation of GSK-3β and apoptosis in vitro and in vivo (12; 49). The
data presented here demonstrate that UB activates Akt and inhibits activation of GSK-3β within
10 min after reoxygenation. Collectively, these data suggest that activation of Akt signaling
pathway may be a key signaling event involved in protecting cardiac myocytes against apoptosis.
Inhibition of GSK-3β attenuates I/R injury by inhibiting mitochondrial permeability transition
pore (mPTP) opening (60). Therefore, it is possible that extracellular UB may inhibit cardiac
myocyte apoptosis by maintaining normal mitochondrial function via the involvement of
AKT/GSK-3β pathway/s.
Low to moderate levels of superoxide are produced during ischemia, followed by a burst
of ROS production at the onset of reperfusion (5; 33). The cardiac myocyte sarcolemma contains
numerous uniport and antiport ion channels along with active transport mechanisms that are
required to maintain cellular pH and membrane potential (44; 50). Evidence has been provided
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that mitochondria serve as the final arbitrators of life or death during an I/R insult. These
organelles are not only required to produce ATP, but they can also trigger both necrosis and
apoptosis (20). Free radicals are produced within minutes of reperfusion and continue to be
generated for hours after the restoration of blood flow to ischemic tissue (6). Oxidant-mediated
cellular injury can lead to damage in the cell membrane, impairment of the cell's ability to
regulate ionic homeostasis, and contribute to mitochondrial injury, leading to a decrement in
oxidative phosphorylation and opening of the mPTP (33). The influx of hydrogen ions into the
mitochondria during hypoxia dissipates the mitochondrial membrane potential (Δψm) and
activates the Na+–H+ exchanger (NHE) causing an elevation in sodium levels. To reduce the
levels of Na+ in the mitochondria, the sodium–calcium exchanger (Na+–Ca2+ exchanger) is
activated, thus introducing Ca2+ into the mitochondria. Upon reperfusion, the Na+–Ca2+
exchanger is reversed and starts extruding Ca2+ from mitochondria (21). It is clear that
mitochondrial dysfunction is a major contributor to loss of myocytes during myocardial ischemia
and subsequent reperfusion. With a reduced number of myocytes, the heart is no longer able to
sustain contractility and heart failure develops (42). Here we show extracellular UB decreases
the ROS and superoxide-positive ARVMs during H/R. It also increases the number of ARVMs
with polarized mitochondria during anoxic conditions. It should be noted, however, that a
significant difference in CTL and UB treatment was only observed 105 min after UB treatment.
The treatment time points should be extended beyond 105 min to observe the protective effect of
UB in preservation of mitochondrial polarization.
Cardiac myocytes and non-myocyte cell populations of the heart express CXCR-4
receptors (10). In leukemia cell line, CXCR-4 is identified as a receptor for UB (46). UB-CXCR4 interaction follows a two-site binding mechanism in which the hydrophobic surfaces
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surrounding Phe-4 and Val-70 are important for receptor binding (47). Previously, we have
shown that the CXCR4 antagonist, AMD3100, inhibits UB-stimulated increases in capillary
network formation, suggesting involvement of CXCR4 receptor for intracellular signaling in
endothelial cells of the heart in response to UB (51). In this study, we show that AMD 3100
negates the effects of UB treatment with respect to apoptosis and activation of Akt and GSK-3β,
suggesting involvement of CXCR-4 in UB signaling. Use of two different UB mutants further
supports the involvement of this receptor in anti-apoptotic signaling pathway induced by UB.

Perspectives
UB is found in normal plasma and is elevated in many diseased states. Previously, we
have shown that extracellular UB plays an anti-apoptotic role in β-AR-stimulated cardiac
myocyte apoptosis in vitro and in vivo (12; 49). The data presented here suggest a protective role
for extracellular UB in I/R-induced cardiac injury and myocyte apoptosis. In the heart, UB
treatment improved functional recovery and decreased activation of STAT-1 and caspase-9
during I/R injury. In vitro, UB treatment activated Akt an anti-apoptotic kinase and decreased
H/R-induced myocyte apoptosis. The data presented here also suggests an important role for
extracellular UB/CXCR4 axis in modulation of oxidative stress and mitochondrial membrane
potential. Further identification of signaling mechanisms leading to UB-mediated regulation of
I/R injury and cardiac myocyte apoptosis may uncover novel strategies to improve cardiac
remodeling and function.
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CHAPTER 5
CONCLUSION
Significant attention is being paid to the development of therapeutics for the treatment
and prevention of ischemia/reperfusion (I/R) injury and myocardial infarction (MI). Clinical
trials are currently underway using therapeutic agents to reduce the adverse effects of cardiac
remodeling caused by I/R injury and MI. Many therapeutic agents and new delivery methods are
currently being investigated to reduce cardiac myocyte apoptosis and fibrosis. The future
development of therapy directed at pathologic and therapeutic I/R injury and MI is dependent
upon a clear understanding of the factors that regulate adverse remodeling of the heart and their
mechanism of action.
Cardiovascular disease is the major cause of morbidity and mortality in the United States.
I/R injury and MI cause adverse cardiac remodeling leading to a decrease in cardiac function.
Cardiac myocytes and resident fibroblast are arguably 2 of the most import cell types of the
heart. Due to the limited mitotic capacity of adult cardiac myocytes, it is important to find ways
to reduce the loss of myocytes during or after injury to the heart. Fibroblasts play a significant
role in wound repair and replacing the loss of myocytes with fibrotic tissue. Collectively, the loss
of cardiac myocytes due to apoptosis and replacement with scar tissue causes the heart to
become stiff reducing the functioning capacity. One way to repair the myocardium would be to
slow or stop the loss of cardiac myocytes and reduce the deposition of fibrotic scar tissue.
Therefore, the foundation for successful therapeutic interventions in I/R injury and MI may lie in
the field of cardiac myocyte apoptosis and cardiac remodeling.
Cardiac sympathetic nerve activity increases following I/R injury and MI (Jardine and
others 2005). Prolonged stimulation of the β-adrenergic neurohormonal axis contributes to the

124

progression of heart failure and mortality in animal models and human patients (Fowler and
others 1986; Singh and others 2001). Stimulation of β-adrenergic receptor (β-AR) increases
expression and activity of matrix metalloproteinase (MMP-2 and MMP-9) in cardiac myocytes in
vitro and in vivo (Menon and others 2005; Krishnamurthy and others 2007). It also induces
apoptosis in cardiac myocytes in vitro and in vivo (Shizukuda and others 1998; Iwai-Kanai and
others 1999; Zaugg and others 2000; Singh and others 2001). β-AR-stimulated apoptosis in
ARVMs is demonstrated to occur via the GSK-3β-/JNK-dependent mitochondrial death pathway
(Remondino and others 2003; Menon and others 2007).
Ubiquitin is a highly conserved protein ~ 8.5 kDa and is found in all eukaryotic cells.
Since UBs discovery over 3 decades ago, research has focused on UB’s role inside the cell. To
date, the most important function of UB is the regulation of protein turnover by the ubiquitinproteasome pathway (Goldberg 2003). However, UB is a normal constituent of plasma and
elevated levels of UB are described in several pathological conditions (Asseman and others
1994; Takagi and others 1999; Akarsu and others 2001a; Akarsu and others 2001b). Previously,
our lab has provided evidence that stimulation of β-AR receptors increases extracellular levels of
UB in adult rat ventricular myocytes (ARVMs), and extracellular UB plays a protective role in βAR-stimulated apoptosis via the inactivation of GSK-3β and JNK pathways (Singh and others
2010). However, the role extracellular UB plays in hypoxia/reoxygenation-induced cardiac
myocyte apoptosis and remodeling has not been elucidated.
The data presented in this study establish a role for extracellular UB in cardiac myocyte
apoptosis and myocardial remodeling following chronic β-AR stimulation in the heart. We found
that exogenous UB plays an important role in β-AR-stimulated myocardial remodeling with
effects on left ventricular function, fibrosis and myocyte apoptosis. The signal transduction
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pathways described within for extracellular UB are depicted in Figure 5.1. We confirm our
previous finding of an antiapoptotic function for UB in vivo and show that UB plays an
important role in β-AR-stimulated myocardial remodeling with effects on left ventricular
function, fibrosis, and myocyte apoptosis. Exogenous UB enhanced activation of antiapoptotic
kinase Akt, while decreasing the activation of proapoptotic kinases, GSK-3β and JNKs.

Figure 5.1 Signal Transduction Pathways for Extracellular UB in β-AR-Stimulated Apoptosis
and Fibrosis. β-AR, β-adrenergic receptor; eUB, extracellular ubiquitin.
Cardiac fibroblast play a critical role in maintaining the normal function of the heart, and
in the remodeling process of the heart that occurs in response to myocardial infarction (Souders
and others 2009). In this study, chronic β-AR-stimulation increased protein levels of MMP-2,
MMP-9, and TIMP-2. In isolated cardiac fibroblast, UB enhanced expression of MMP-2 and
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TIMP-2. UB activated Akt and inhibition of Akt decreased MMP-2 expression. We also present
evidence that extracellular UB modulates cardiac fibroblast phenotype and function and
define a role CXCR4 receptor plays in modulating fibroblast phenotype and function in
response to extracellular UB. UB interacts with fibroblast and CXCR4 receptors, induces
cytoskeletal reorganization, induces intracellular signaling of ERK1/2, and inhibits migration of
fibroblast into the wound. The fibroblast migration may be because UB decreases expression of
β3 integrin, a protein involved in fibroblast migration. This may explain the reduction of fibrosis
in UB treated β-AR-stimulated hearts.
Apoptosis is programmed cell death and is very organized. It has been reported that after
MI or ischemic event, left ventricular (LV) dysfunction occurs, in part, as a result of ongoing
cardiac myocyte apoptosis (Sharov and others 1996). Cardiac myocyte apoptosis occurs at an
increased rate after injury due to I/R and MI (Olivetti and others 1997). However, the
mechanisms of cardiac myocyte apoptosis leading to remodeling are not fully understood. In this
study, we present evidence that extracellular UB plays a role in I/R injury in isolated hearts and
cardiac myocytes. The data suggest extracellular UB protects the heart by decreasing infarct
size, improving functional recovery of the heart, and decreasing activation of STAT-1 and
caspase-9. In vitro, UB treatment decreases H/R-induced myocyte apoptosis, activates Akt
while inactivating GSK-3β, decreases oxidative stress and improves the number of
myocytes with polarized mitochondria. Most of these effects of UB are negated by CXCR-4
antagonist AMD 3100. Mutated UB, unable to bind CXCR-4 has no effect on H/R-induced
apoptosis, intracellular signaling, or oxidative stress. Collectively, the data presented in this
study shows evidence that extracellular UB modulates chronic β-AR-stimulated myocardial
remodeling, fibroblast function, and I/R injury in isolated hearts and myocytes.
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Possible future directions for this field of study are numerous. The current study
examined the role of exogenous UB 7 days after chronic β-AR stimulation. This time point
should be extended beyond 7 days to investigate if UB continues to decrease cardiac
myocyte apoptosis, fibrosis, and sustain myocardial function. Analysis of components of
extracellular matrix, including collagen type I and IV, laminin, fibronectin, etc. may provide
insight into the modulation of heart function in the presence of exogenous UB. In isolated
fibroblast, AMD 3100 almost completely inhibits UB-mediated increases in β3 integrins and
VEGF-A expression. However, inhibition of ERK1/2 was partial. Further investigation should be
carried out to determine if this differential response is caused by differences in binding affinities
for AMD 3100 and UB or incubation durations. The langendorff global I/R injury is a good
model to remove any potential confounding effects derived from systemic actions of the heart.
However, the next logical step for I/R injury model would be to move into an animal model of
I/R injury. All the current findings have been executed using extracellular UB as a pretreatment
before insult. It would be interesting to see if extracellular UB has the same effects postinsult to
the heart. Further identification of signaling mechanisms leading to UB-mediated regulation of
I/R injury and cardiac myocyte apoptosis may uncover novel strategies to improve cardiac
remodeling and function. The structural changes related to cardiac myocyte apoptosis and
extracellular matrix play a significant role in modulation of myocardial function and in the
progression to heart failure. Therefore, elucidation of processes that can shift the balance from
myocyte apoptosis to survival may have clinical implications.
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